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25(OH)D 25-hydroxyvitamin D 
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dP/dt maximal change in blood pressure 
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ESC European Society of Cardiology 
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hsCRP high-sensitivity C-reactive protein 
IU international unit 
MAP mean arterial pressure 
NAD nicotinamide adenine dinucleotide 
NADH reduced nicotinamide adenine dinucleotide 
NADPH reduced nicotinamide adenine dinucleotide phosphate 
NMMA NG-monomethyl-L-arginine 
NO nitric oxide 
NOS nitric oxide synthase 
NTG nitroglycerin 
OSI oxidative stress index 
OxS oxidative stress 
PE phenylephrine 
PP pulse pressure 
PPAR-γ peroxisome proliferator-activated receptor-gamma 
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PTH parathyroid hormone 
PWA pulse wave analysis 
PWV pulse wave velocity 
RAGE receptor for advanced glycation end-products 
RAS renin-angiotensin system 
ROS reactive oxygen species 
SBP systolic blood pressure 
STZ streptozotocin 
T1DM type 1 diabetes mellitus 
T2DM type 2 diabetes mellitus 
TAC total antioxidant capacity 
TMB tetra-methyl-benzidine 
TPX total peroxides 
UVB ultraviolet B 
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The physiological function of vitamin D in the maintenance of calcium homeo-
stasis and bone metabolism is well-recognised (Holick et al. 1972; Boyle et al. 
1972). Concurrent studies on vitamin D metabolism have identified the vitamin 
D receptor (VDR) expression in a variety of tissues and cells, including, but not 
limited to, the pancreatic β-cells, immune cells, vascular endothelial cells, 
cardiomyocytes, and neurons (Walters 1992). These findings support the view 
that vitamin D has beneficial effects on other important functions in organs and 
tissues not inherently associated with calcium metabolism. Clinical studies have 
reported an inverse relationship between vitamin D status and incidence of 
cardiovascular disease (CVD) (Scragg et al. 1990; Zittermann et al. 2003), 
while replenishing vitamin D stores has been shown to reduce blood pressure 
(BP) and left ventricular hypertrophy (Pfeifer et al. 2001; Park et al. 1999). The 
relevance of maintaining adequate vitamin D status is highlighted by epidemio-
logical studies demonstrating high prevalence of vitamin D insufficiency in 
Northern Europe (Barger-Lux and Heaney 2002; Kull et al. 2009). 
 Arterial stiffening is a manifest of adverse structural and functional modi-
fications within the arterial wall that develop with advancing age and in the pre-
sence of cardiovascular (CV) risk factors (Laurent et al. 2006). Large artery 
stiffness is a powerful predictor of CVD progression and is now considered an 
independent CV risk factor and a target for therapy (Blacher et al. 1999; 
Laurent et al. 2001a; Mattace-Raso et al. 2006). Detection of changes within the 
arterial wall using different diagnostic methods enables to identify patients at 
risk of CV complications and allows early prevention and intervention in the 
progress of CVD. A variety of methods are available for assessment of arterial 
stiffness. Pulse wave velocity (PWV) is an index of arterial stiffness that can be 
measured with high accuracy and reproducibility in experimental animals and 
human subjects. The acknowledgment of using PWV as a marker of asympto-
matic target organ damage and an integral tool for diagnosis and risk stratifi-
cation is evidenced by its inclusion in the 2007 and 2013 European guidelines 
for management of arterial hypertension (Mancia et al. 2007; Mancia et al. 
2013). 
 Morbidity and mortality of patients with diabetes mellitus (DM) are mainly 
determined by the development of vascular complications as a result of three-
fold increased CV risk compared to general population (Stamler et al. 1993). 
The deleterious impact of diabetic vascular complications warrants early 
detection of abnormalities in the vascular structure and function and early 
interventional strategies. Prevention and treatment of diabetic vascular damage 
by correcting underlying metabolic abnormalities is the mainstay in the treat-
ment of DM. However, pharmacological interventions may be of limited value 
in the modulation of complications once they have developed. For this purpose, 
studying the pathogenesis of diabetic vascular complications in experimental 
animal studies provides valuable means for understanding of the course of the 
disease and finding new targets for intervention. 
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 Long-term hyperglycaemia, one of the hallmarks of DM, induces non-enzy-
matic modifications of proteins and other biomolecules, producing advanced 
glycation end-products (AGEs) and their deposition in tissues, including the 
arterial wall (Brownlee et al. 1984). Modification of extracellular matrix 
proteins, including collagen and elastin, impairs the biomechanical integrity of 
the arterial wall and subsequently decreases arterial elasticity (Mizutani et al. 
1999). The formation of AGEs is exacerbated by concurrent high-grade oxida-
tive stress (OxS), which overwhelms the capacity of antioxidant defence to 
counterbalance elevated OxS (Mullarkey et al. 1990). Collectively, the OxS-
AGE axis is considered central in the development of DM-induced vascular 
complications (Brownlee 2005), and therapeutic strategies targeted at different 
steps of AGE formation may significantly improve DM-induced vascular 
damage. 
 The activated renin-angiotensin system (RAS) is an important contributor to 
adverse vascular outcomes in DM (Miller 1999). The interplay between angio-
tensin II-induced vasoconstriction and arterial wall remodelling via non-
haemodynamic mechanisms leads to arterial stiffening (Dzau et al. 1991; 
Griffin et al. 1991). The RAS blockers (e.g., angiotensin converting enzyme 
inhibitors [ACEIs] and angiotensin II type 1 receptor blockers [ARBs]) are 
well-established agents for treatment of hypertension, but they also have equally 
important effects beyond BP reduction (UK Prospective Diabetes Study Group 
1998; Brenner et al. 2001). Among ARBs, telmisartan may be distinguished as 
a favourable agent for use in patients with DM owing to its profile of cardio-
metabolic protection (Yamagishi and Takeuchi 2005; Derosa et al. 2004). 
Collective evidence suggests that telmisartan may provide unique possibilities 
for the prevention and treatment of DM-associated vascular complications. 
The main purpose of the current thesis was to investigate the role of vitamin 
D in the arterial structure and function in experimental DM and in well-trained 
human subjects, as well as to study the effect of an ARB telmisartan on arterial 
damage associated with experimental DM. 
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2. REVIEW OF THE LITERATURE 
2.1. Vitamin D 
Vitamin D belongs to a group of lipid-soluble sterol-like compounds, with the 
two most important forms being vitamin D2 (ergocalciferol), which is obtained 
from plant products, and vitamin D3 (cholecalciferol), which is produced by the 
skin as a result of ultraviolet B (UVB) radiation or obtained from animal 
sources. Vitamin D is biologically inactive in humans and requires conversion 
to the pro-hormone 25-hydroxyvitamin D (25[OH]D) in the liver (Henry 1992). 
This pro-hormone is then further converted into the active hormone 1,25-
dihydroxyvitamin D or calcitriol by the enzyme 1α-hydroxylase which takes 
place mainly in the renal tubular epithelium (Henry 1992). Vitamin D and its 
metabolites are transported in the blood bound to the vitamin D binding protein 
to its effector sites. The biological actions of calcitriol are mediated by the 
nuclear VDR that is present in various tissues, including the heart, brain, skin, 
and pancreas (Baker et al. 1988; Walters 1992). 
 
 
2.1.1. The role of vitamin D in health and disease 
2.1.1.1. Calcium metabolism 
The main function of vitamin D is the regulation of calcium homeostasis in the 
organism. Calcium is one of the most tightly regulated substances in the plasma 
because its concentration as ionised calcium is maintained constantly within a 
narrow range (Jones et al. 1998). Calcium is essential for a variety of metabolic 
processes, including muscle contraction, neurotransmission, signal transduction, 
coagulation, enzyme activation, and maintenance of osmotic pressure in the 
blood (Holick 2003). In response to even a slight decrease in plasma calcium 
level the parathyroid glands react to secrete the parathyroid hormone (PTH) that 
initiates a sequence of events resulting in mobilisation of calcium to restore its 
level in the plasma. In the kidneys, PTH activates the conversion of 25(OH)D to 
the active hormone calcitriol (Garabedian et al. 1972). Calcitriol is transported 
to the small intestine where it increases the expression of calcium channels and 
calcium binding protein, thereby enhancing the absorption of calcium from the 
food (Boyle et al. 1972). Calcitriol also stimulates osteoclasts which results in 
increased bone resorption and increased mobilisation of calcium from the bone 
tissue to plasma (Holick et al. 1972). In the distal renal tubule, calcitriol, in 
concert with PTH, increases the reabsorption of calcium into the plasma 
(Yamamoto et al. 1984). Negative feedbacks from increasing plasma calcium 






2.1.1.2. Cardiovascular diseases 
The importance of vitamin D in calcium homeostasis and bone metabolism is 
well established. With increasing number of studies investigating the influence 
of vitamin D on non-classical target tissues a wide range of non-calciotropic 
actions of vitamin D has been discovered. The biological plausibility of these 
activities is supported by the findings of VDR, a transcription factor, expression 
in a variety of cells, including pancreatic β-cells, immune cells, myocytes, 
cardiomyocytes, endothelial cells, and neurons (Walters 1992). 
 There is substantial evidence to support the implication of vitamin D in the 
pathogenesis of CVD (Watson et al. 1997; Zittermann et al. 2005; Lee et al. 
2008). Calcitriol is a negative regulator of renin expression and thereby inhibits 
the RAS, which is an important contributor to the development of arterial 
hypertension (Li et al. 2002). Vascular effects of calcitriol include the modu-
lation of smooth muscle proliferation (Mitsuhashi et al. 1991) and inhibition of 
vascular calcification (Watson et al. 1997). Calcitriol is also known to regulate 
the cellular production of pro-inflammatory (e.g., interleukin-1 and tumour 
necrosis factor-alpha) and anti-inflammatory cytokines (e.g., interleukin-10), a 
mechanism that may be important in the prevention of CVD (Müller et al. 1992; 
Canning et al. 2001). 
 Pharmacological, but not physiological, doses of vitamin D have been 
reported to cause hypertension, arterial stiffening, and atherosclerosis in rodent 
models; however, the importance of these findings for humans is uncertain 
(Norman and Powell 2005). Vitamin D toxicity and the resultant hyper-
calcaemia, which can lead to arterial stiffening and hypertension, have been 
observed when circulating 25(OH)D levels are higher than 374 nmol/L (Holick 
2007). Data from clinical trials have not shown vitamin D toxicity with daily 
doses of up to 10,000 international units (IU) vitamin D which approximates the 
level of vitamin D production that can be achieved by endogenous vitamin D 
synthesis in the skin (Vieth 1999; Heaney et al. 2003). 
Cross-sectional studies investigating the association between vitamin D 
status and CVD risk have demonstrated low levels of vitamin D in individuals 
with acute myocardial infarction (Scragg et al. 1990), stroke (Poole et al. 2006), 
heart failure (Zittermann et al. 2003), hypertension (Scragg et al. 2007), and 
peripheral artery disease (van de Luijtgaarden et al. 2012). In clinical trials, 
vitamin D supplementation has been shown to decrease BP (Lind et al. 1989; 
Pfeifer et al. 2001) and left ventricular hypertrophy (Park et al. 1999). However, 
there is relatively little information regarding the role of vitamin D in arterial 
stiffness. Vitamin D deficiency has been correlated with increased aortic stiff-
ness in patients with end-stage renal disease (London et al. 2007) and carotid 
artery calcification (Freedman et al. 2010). Inverse relationships between serum 
25(OH)D levels and aortic stiffness have been shown in healthy subjects (Al 
Mheid et al. 2011) and in general population (Mayer et al. 2012). Interventional 
studies have produced conflicting results, reporting either improvement of 
arterial stiffness (Dong et al. 2010) or no effect of vitamin D supplementation 
on arterial stiffness (Larsen et al. 2012; Stricker et al. 2012). In this thesis, we 
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have investigated the association between vitamin D status and arterial stiffness 
in experimental DM (Paper I) and in healthy individuals (Paper IV). 
 
 
2.1.2. Environmental determinants of vitamin D status 
Vitamin D insufficiency is an increasingly recognised worldwide health prob-
lem (Holick 2005). Vitamin D status in the organism is assessed by the con-
centration of its circulating metabolite 25(OH)D since its level is mainly 
regulated by substrate availability (Zittermann 2006). Serum concentration of 
25(OH)D is dependent on several modifiable and non-modifiable factors such 
as diet, latitude, season, time spent outdoors, skin pigmentation, clothing, and 
tanning habits (Sherman et al. 1990). 
Ultraviolet B radiation initiates vitamin D production in the skin. The 7-
dehydrocholesterol, a cutaneous membrane lipid, absorbs UVB radiation and is 
converted into pre-vitamin D, which will isomerise into cholecalciferol (Holick 
and DeLuca 1974). Vitamin D intoxication due to prolonged exposure to UVB 
is not possible because any excess vitamin D is converted to inert isomers in the 
skin (Webb et al. 1989). Increasing latitude decreases the availability and 
intensity of UVB radiation. At latitudes above 40° (the latitude of Estonia is  
59° N), synthesis of vitamin D is absent during winter and is blunted even in the 
summer months (Barger-Lux and Heaney 2002). In a recent cross-sectional 
study in Estonia, the prevalence of vitamin D insufficiency and deficiency were 
73% and 8%, respectively (Kull et al. 2009). This indicates that Estonian 
population is at high risk for vitamin D deficiency. 
While most of vitamin D in the organism is synthesised by the skin, food is 
also a considerable source of vitamin D. Fish and fish products are among the 
best sources of vitamin D3, small amounts are also found in cheese and egg 
yolks (Lamberg-Allardt 2006). Food fortification (mostly dairy products) and 
vitamin D supplements are also increasingly common in many countries. 
The cut-off value for normal circulating 25(OH)D levels has been a subject 
of much dispute. Vitamin D insufficiency is most commonly defined by serum 
25(OH)D level below 50 nmol/L (Holick 2007), but there are also studies sug-
gesting that 25(OH)D level less than 37.5 nmol/L should be considered inade-
quate (Jacques et al. 1997; Thomas et al. 1998). However, a number of recent 
studies suggest that 25(OH)D level above 75 nmol/L should be considered ideal 
in regard of bone metabolism and non-calcaemic functions of vitamin D 
(Chapuy et al. 1997; Bischoff-Ferrari et al. 2006; Bischoff-Ferrari 2007). In 
these studies, this level of 25(OH)D was found to be efficient in maintaining 
normal PTH secretion, considering that high levels of PTH may have adverse 
effects on the CV system by promoting ventricular hypertrophy (Schlüter and 





2.2. Aortic stiffness 
Large arteries, in particular the aorta and its main branches, are regarded as a 
complex organ with distinct functions, regulating blood flow and BP as well as 
buffering the pulsations generated by the heart (Nichols and O'Rourke 2005). 
The buffering function is the essential ability of large arteries to accommodate 
the blood volume ejected by the heart and absorb the energy generated by the 
pulsation, thereby reducing the load on the left ventricle and providing a steady 
blood flow to the peripheral organs. With increasing age, athero- and arterio-
sclerosis, and hypertension, functional and structural modifications occur within 
the arterial wall, resulting in increased arterial stiffness (Laurent 1995; 
O'Rourke 1995). These changes predominantly appear in the central elastic 
arteries than in the distal muscular arteries (Benetos et al. 1993). Stiffening of 
the aortic wall impairs the inherent ability of the aorta to expand and convert 
pulsatile blood flow ejected from the heart into a continuous blood flow to the 
peripheral organs. Increased aortic stiffness also increases the left ventricular 
afterload leading to impaired contractility and heart failure (O'Rourke 1982; 
Roman et al. 2000; Nitta et al. 2004). Aortic stiffness is predictive of CV morta-
lity and all-cause mortality, in a range of high-risk patients (Laurent et al. 
2001a; van Popele et al. 2001) and in general population (Mattace-Raso et al. 
2006). The utility of assessment of aortic stiffness in clinical practice is 




2.2.1. Aortic wall morphology 
The capacitance and resistance of the aorta are determined by the geometry, 
proportion, and action of the components of the aortic wall. The aortic wall con-
sists of three layers: tunica intima, tunica media, and tunica adventitia. The ad-
ventitia is the outmost layer consisting of collagen fibres and extracellular 
matrix components. The media contains vascular smooth muscle (VSM) cells 
embedded in the network of collagen and elastin fibres. The intima is composed 
of a monolayer of endothelial cells lining the lumen of the vessel, anchored to 
the internal elastic lamina by the subendothelial layer of elastin and collagen 
fibres. 
 Each of the wall layers has a distinctive role in the regulation of arterial 
function. The adventitia, abundant with longitudinally arranged elastin and 
collagen bundles, provides mechanical support and serves as a connection to 
surrounding tissues. The medial layer contributes to circumferential stiffness of 
the aorta. The spatial arrangement and quantity of collagen and elastin fibres in 
the media are important in determining the overall mechanical properties of the 
aortic wall. At low distending pressure, the majority of the load is transferred to 
elastic fibres. The elastic fibres extend proportionally to the distending pressure 
(Wolinsky and Glagov 1967). As the pressure increases, stiffer collagen fibres 
are being gradually recruited, and their stiffness limits the aortic distension 
17 
(Clark and Glagov 1985; Armentano et al. 1991). The resultant classic non-
linear relationship between the stress applied to the aortic wall and change of 
aortic diameter (the increase in diameter is reduced with increasing pressure) 
can be assigned to the different elastic properties of both elastin and collagen 
fibres in the aortic media (Figure 1). Collagen fibres in the adventitia are not 




Figure 1. Schematic representation of a typical stress-strain relationship of an elastic 
artery, reproduced from Åstrand 2008. The contribution of collagen (c – dashed line) 
and elastin (e – dotted line) fibres constitute the biphasic global response of the arterial 
wall to the applied stress (solid line). 
 
 
The distribution of load bearing components, elastin, collagen, and VSM, varies 
along the arterial tree. Elastin is the major component in the proximal part of the 
aorta, while collagen dominates in the distal aorta and remains relatively 
constant in the peripheral arteries (Harkness et al. 1957; Apter et al. 1966). 
Vascular smooth muscle content is lower in the proximal arteries than those 
more distal to the heart. In the aorta and other large arteries, VSM is helically 
arranged, while the alignment in the distal arteries is more circumferential 
(Milnor 1982). Due to proportion and structure of the load bearing components, 
large arteries more proximal to the heart are inherently more elastic than the 
distal arteries (Latham et al. 1985). These properties are essential in the arterial 
haemodynamics, as the aorta has a capacitive function, buffering the stroke 
volume and continuously supplying blood to the peripheral organs, while 
limiting the load on the left ventricle. Changes in the aortic wall geometry, both 
quantitatively and qualitatively, lead to increased stiffness of the vessel wall, as 
seen in the ageing aorta (Benetos et al. 1993; Boutouyrie et al. 1992; Länne et 
al. 1992). This aortic remodelling occurs in response to chronic applied stress 
such as pulse pressures imposed on the vessel wall (Laurent et al. 2001b), 
leading to degeneration of the wall structure. Increased aortic stiffness is 
characterised by fracture and degradation of elastic fibres and increased loading 














of aortic remodelling include hypertension (Benetos et al. 1993; Avolio et al. 
1998), atherosclerosis (van Popele et al. 2001; Zagura et al. 2011), and end-
stage renal disease (Blacher et al. 1998). 
 
 
2.2.2. Functional properties of the aorta 
In addition to passive load bearing structural components, elastin and collagen, 
aortic wall also contains functional, dynamic component, smooth muscle. Dyna-
mic alteration in aortic stiffness is mediated by changes in VSM tone induced 
by exogenous or endogenous chemical signalling pathways. There are two 
distinct phenotypes of VSM cells: contractile and synthetic (Shanahan and 
Weissberg 1998). Contractile VSM cells contain contractile filaments, while 
synthetic VSM cells have a high number of organelles required for protein 
synthesis (Hao et al. 2003). Contractile VSM cells may transform into synthetic 
phenotype which is regarded as a precondition for development of vascular 
disease (Shanahan and Weissberg 1998). 
 The vascular endothelium has an important role in the regulation of arterial 
function by producing vasoactive substances, including nitric oxide (NO), an 
important vasodilator that mediates VSM tone (Lekakis et al. 2011). The nitric 
oxide, synthesised from L-arginine by endothelial NO synthase (NOS), is the 
main vasodilating and major antiatherogenic biomolecule in the arterial wall 
(Davignon and Ganz 2004). Endothelial NO also inhibits platelet aggregation, 
cell adhesion, and the proliferation of VSM cells, thereby preventing vascular 
remodelling (Moncada et al. 1991). Under basal conditions, NO synthesis is 
continuously stimulated by shear stress on endothelial cells, and the release of 
NO is responsible for maintenance of VSM relaxation (Haynes et al. 1993; 
Kinlay et al. 2001). Exogenous NO donors such as nitroglycerin (NTG) release 
NO directly and act on VSM similarly to endogenously produced NO (Ignarro 
2002). Overall, the continuous generation of NO by the endothelium is essential 
for the maintenance of aortic elasticity, while inhibition of NO production has 
been shown to increase the stiffness of the aortic wall (Wilkinson et al. 2002). 
 
 
2.2.3. Pulse wave velocity 
The contraction of the left ventricle generates a pressure pulse wave that travels 
along the arterial wall throughout the body. The velocity at which the pulse 
wave propagates along the artery is dependent on the physical properties and 
geometry of the arterial wall. Hence, the velocity of pulse wave propagation 
provides an index of arterial distensibility and stiffness so that higher velocity 
corresponds to higher arterial stiffness. Pulse wave velocity can be simply 
calculated by dividing the distance between the two sites at which the pressure 
pulses are being recorded with time needed by the wave front to travel between 
those two sites. 
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 Assessment of PWV is very useful in the evaluation of changes in the 
vascular system because increasing age (Avolio et al. 1983) and various di-
seases are known to affect the stiffness of the arteries. Several large studies have 
demonstrated that PWV is an independent predictor of all-cause and CV 
mortality in patients with hypertension (O'Rourke 1982), DM (Mattace-Raso et 
al. 2006), and end-stage renal disease (Blacher et al. 1999). The importance of 
PWV is not limited to specific disease groups. Increased PWV has also been 
shown to predict CV mortality in general population (Willum-Hansen et al. 
2006). Accordingly, PWV can be regarded as a useful diagnostic tool in diffe-
rent clinical settings. The importance of aortic PWV in the assessment of aortic 
stiffness is illustrated by inclusion of PWV measurement in the European 
Society of Cardiology (ESC) and the European Society of Hypertension (ESH) 
guidelines for assessment of asymptomatic target organ damage in arterial 
hypertension (Mancia et al. 2007; Mancia et al. 2013). Reference values for 
aortic PWV have been published recently to help identify people with higher 
CV risk (Boutouyrie and Vermeersch 2010). 
Pulse wave velocity assessment is dependent on several critical factors, 
including accurate measurement of distance between the recording sites, 
consistent determination of the pressure wave front, and the dependency of 
PWV on distending pressure. The distance between the two pressure sensors in 
non-invasive PWV measurements in human subjects can be estimated by direct 
superficial measurement (over the skin) with acceptable accuracy owing to 
relatively long distances between the two sites. In experimental studies using 
small animals, inaccurate measurement of short distances may introduce a 
significant error in PWV calculations. These errors can be eliminated by 
simultaneous recording of the pulse waves using a high-fidelity dual pressure 
sensor catheter with two pressure sensors fixed an exact distance apart. 
Accurate determination of the wave front is important because of continuous 
changes in the pulse contour as it travels due to viscoelastic properties of the 
arterial wall and wave reflection. The forward propagating wave is reflected 
from sites of impedance mismatch in the arterial tree as present at branchings 
and segments with tapering or changes in vessel wall stiffness. The peak of the 
pulse wave is not practical for calculating PWV because it is strongly affected 
by the wave reflection (Nichols and O'Rourke 2005). The foot of the pressure 
wave is regarded to be relatively free of reflections because of the time delay 
between the forward and backward propagating waves. The pressure wave foot-
to-foot measurement of PWV (Figure 2) is used throughout this thesis due to its 










































































































































































































































































It is well established that PWV is a complex function of arterial wall structure, 
vasomotor tone, and transmural pressure (Shadwick 1999). Therefore, PWV 
varies as a function of arterial pressure at which it is measured. This means that 
comparison of PWV between individuals should be made in isobaric conditions. 
In animal experiments, manipulation of arterial pressure is feasible through in-
fusion of pharmacological agents, e.g., phenylephrine (PE) and NTG, for in-
creasing and decreasing arterial pressure, respectively. Due to nonlinear elastic 
properties of the arterial wall, measuring PWV at an arbitrarily chosen pressure 
may provide limited information compared to the assessment of PWV over a 
wide range of arterial pressures. In recent years, pressure-dependent PWV 
measurement has gained increasing use as a standard for the assessment of 
aortic stiffness in a range of experimental settings (Ng et al. 2011; Tan et al. 
2012; Jung et al. 2013). In this thesis, we have investigated aortic stiffness 
assessed by PWV under pressure-independent conditions in a rat model of type 
1 DM (T1DM) (Papers I and II). 
 
 
2.2.4. Arterial stiffness and inflammation 
Systemic inflammation has been established as a major contributor for athero-
sclerotic processes (Libby et al. 2002) and is considered a risk factor for CVD 
(Ridker et al. 1997; Willerson and Ridker 2004). Inflammation is associated 
with endothelial dysfunction since activated inflammatory system is paralleled 
by decreased NO availability and normalisation of inflammatory activity has 
been shown to improve endothelium-dependent vasodilation (Yki-Järvinen et 
al. 2003; Fichtlscherer et al. 2000). Circulating markers of inflammation, 
including C-reactive protein (CRP), have been shown to be associated with 
arterial stiffness indices such as augmentation index (AIx) (Kampus et al. 2004; 
Kampus et al. 2006; Kampus et al. 2007) and aortic and brachial PWV 
(Mattace-Raso et al. 2004; Yasmin et al. 2004) in various sub-populations. Si-
milar correlations have been demonstrated between circulating pro-inflam-
matory cytokine interleukin-6 levels and aortic PWV in patients with arterial 
hypertension (Mahmud and Feely 2005) and in general population (Schnabel et 
al. 2008). Paper IV addresses the relationship between inflammation and arterial 




2.3. Investigation of vascular complications  
in diabetes mellitus 
Diabetes mellitus represents one of the most common public health problems 
affecting more than 350 million people worldwide at an increasing rate (Danaei 
et al. 2011). Diabetes mellitus comprises a group of metabolic diseases mainly 
characterised by elevated blood glucose either because of insufficient pro-
duction of insulin (T1DM) and/or decreased response of cells to insulin 
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(T2DM). Regardless of the classification, the resulting metabolic abnormalities 
of DM are associated with 2–4 fold higher CV risk than in general population 
even after adjustment to other known CV risk factors (Stamler et al. 1993). 
Vascular complications of DM represent the principal cause of morbidity and 
mortality. Due to the natural course of DM, it takes years for the complications 
to develop which makes it difficult to assess the effects of the interventions to 
modulate the development of complications. This concern may be addressed by 
studying DM in animal models which also has the advantage to eliminate such 
factors as ethnicity, geographic variables, diet, age and gender differences, and 
drug interactions that inevitably set limits to clinical studies. Studying DM in 
experimental settings is fundamental for the advancement of knowledge of its 
pathogenesis and finding new therapies for DM and its complications. 
 
 
2.3.1. Streptozotocin-induced model of type 1 diabetes mellitus 
Streptozotocin (STZ) is a metabolite from Streptomyces Achromogenes with 
antibiotic, antitumour, and carcinogenic properties. STZ is composed of the 
cytotoxic moiety, 1-methyl-1-nitrosourea, attached to the C-2 position of D-
glucose. The glucose moiety is an important factor that specifically directs STZ 
toxicity to the β-cells, sparing α-cells and δ-cells (Agarwal 1980), by mediating 
the uptake of STZ via the glucose transporter GLUT2 (Schnedl et al. 1994). 
The diabetogenic action of STZ was first reported on 1963 (Rakieten et al. 
1963). The finding of its selective toxicity to β-cells in the pancreatic islets sug-
gested that the drug can be used for inducing DM in animal models (Mansford 
and Opie 1968). Since then, it has been used in numerous studies, probably 
making it the second most used animal model of human disease, after the 
spontaneously hypertensive rat. 
 Acting as an alkylating agent, STZ has been shown to interfere with glucose 
transport (Wang and Gleichmann 1998) and glucokinase function (Zahner and 
Malaisse 1990) and to cause multiple deoxyribonucleic acid (DNA) strand 
breaks (Bolzan and Bianchi 2002). A single large dose of STZ can be used to 
produce hyperglycaemia in experimental animals, evidently due to direct toxic 
effects on β-cells (Junod et al. 1967). Alternatively, multiple low doses of STZ 
can be used which leads to insulitis and death of β-cells (Like and Rossini 
1976). The metabolic abnormalities after administration of STZ doses of 50– 
65 mg/kg body weight are characteristic to those seen in patients with T1DM. 
Hyperglycaemia (20–30 mmol/L) is observed within 48 hours concomitantly 
with a decrease in blood insulin levels, but severe ketosis does not develop, 
even if insulin is not administered (Junod et al. 1969). Higher doses of STZ 
(>75 mg/kg body weight) result in fatal ketosis within days if insulin is not 






2.3.2. Endothelial dysfunction 
Disturbed endothelial function is generally defined as the imbalance between 
vasoconstricting and vasodilating substances released by the endothelial cells 
(Deanfield et al. 2005). Endothelial dysfunction is a common characteristic in 
patients with atherosclerosis (Kals et al. 2006a) and DM (Dogra et al. 2001) and 
a critical factor for the development of CVD (Gokce et al. 2003) and diabetic 
vascular complications (Johnstone et al. 1993). 
 The synthesis of NO, a major endothelial-derived vasodilative substance, is 
dependent on its substrate, L-arginine. Two types of endogenous competitive 
inhibitors of NOS are present in the circulation, NG-monomethyl-L-arginine (L-
NMMA) and asymmetric NG,NG-dimethyl-L-arginine (ADMA) (Vallance et al. 
1992). Higher concentrations of ADMA in plasma suggest that the latter is the 
major endogenous NOS inhibitor, compared to L-NMMA. Reduced NO 
synthesis leads to impaired endothelium-dependent vasodilation (Giugliano et 
al. 1996), thus contributing to increased CV morbidity. 
 The utility of the measurement of ADMA as a surrogate marker of endo-
thelial dysfunction has been demonstrated in studies using venous occlusion 
plethysmography (Juonala et al. 2007) and flow-mediated dilation (Perticone et 
al. 2005) that are both well-established methods for assessment of endothelial 
function. Endothelial vasodilatory dysfunction and accumulation of ADMA 
may be important mechanisms underlying reduced arterial elasticity in healthy 
subjects (Kals et al. 2007). Elevated levels of ADMA have been reported in a 
wide range of clinical conditions associated with increased CV risk, including 
hypertension (Goonasekera et al. 1997), peripheral artery disease (Böger et al. 
1997), pulmonary hypertension (Gorenflo et al. 2001), chronic heart failure 
(Kielstein et al. 2003), and cerebral small vessel disease (Khan et al. 2007). 
Asymmetric dimethylarginine has been shown to predict all-cause mortality in 
healthy subjects (Böger et al. 2009) and CV events in patients with coronary 
artery disease (Schnabel et al. 2005) and peripheral artery disease (Mittermayer 
et al. 2006). 
 
2.3.3. Structural changes in the aorta 
Short-term reversible functional changes in the aortic distensibility are mediated 
by alterations in the endothelium-dependent smooth muscle tension. During 
contraction, smooth muscle cells transfer stress to collagen, while elastin 
lamellae are the load-bearing elements during relaxation (O'Rourke and Avolio 
1985). Over longer periods of time, the aortic wall undergoes changes in the 
spatial arrangement and quantities of smooth muscle, elastin, and collagen, 
which leads to mechanical adaptation to chronic applied forces such as pulse 
pressures altering aortic wall stiffness, wall thickness, and luminal diameter 
(Mulvany 1993). These changes, if observed morphologically, are considered 
essential for defining vascular remodelling (Lee et al. 1997). 
 Vascular remodelling is a fundamental basis of normal vessel growth and 
adaptation. However, the mechanical properties of the aorta and resistance 
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arteries gradually decline with increasing age in parallel with increasing aortic 
stiffness (Mitchell et al. 2007). Abnormalities in the vascular structure as-
sociated with DM have been described as accelerated aging (Lee and Oh 2010). 
Diabetes mellitus is known to induce modifications of extracellular matrix 
proteins such as collagen and elastin (Reddy 2004) that may compromise the 
biomechanical integrity of the vessel wall and consequently alter vascular 
elasticity (Mizutani et al. 1999). This thesis investigates two specific aspects of 
aortic wall remodelling, namely the quantitative and qualitative changes in the 
elastin and collagen fibres (Papers I and II). 
 
 
2.3.4. Advanced glycation end-products in diabetes mellitus 
Long-term high levels of glucose in blood and tissues induce non-enzymatic 
modifications of proteins, lipids, and nucleic acids, forming AGEs through a 
series of reactions (Vlassara et al. 1984; Brownlee et al. 1984). Protein gly-
cation is initiated by a reaction between a free amino group and the carbonyl 
group of glucose to form a reversible Schiff base (within hours). Over a period 
of days, the latter rearranges into a more stable ketoamine or Amadori product 
(Brownlee et al. 1984). The Amadori product can be fragmented by oxidation to 
produce a number of highly reactive compounds such as Nε-(carbo-
xymethyl)lysine (CML) or pentosidine which react again with other free amino 
groups thus forming different intermediate and advanced glycation end-products 
(McCance et al. 1993; Reddy et al. 1995). While the process of early protein 
glycation is dependent on ambient glucose levels, the contribution of oxidative 
stress becomes more important in the development of AGEs (Baynes 1991). 
Advanced glycoxidation occurs over a period of weeks or even months, thereby 
affecting proteins with a slow turnover. Structural components of the connective 
tissue matrix such as collagen and elastin are the prime targets of advanced 
glycation (Brownlee et al. 1984). 
A common consequence of irreversible AGE formation is the accelerated 
development of covalent cross-links between structural proteins (Fu et al. 
1994). The pathological formation of cross-links induced by AGEs increases the 
stiffness of the tissue. Several studies have indicated that accumulation of AGEs 
in the vascular wall, rather than quantitative changes in the structural proteins, 
contribute to the mechanical properties of the vascular wall. The amount of 
AGEs in the aortic wall has been positively correlated with wall stiffness in 
experimental (Brüel and Oxlund 1996) and human studies (Sims et al. 1996) 
suggesting that AGEs may be one of the causative factors of reduced aortic 
elasticity in DM. Advanced glycation end-products have also been implicated in 
other diabetic complications, including retinopathy (Stitt 2003), nephropathy 
(Sugiyama et al. 1996), and neuropathy (Sugimoto et al. 1997). Besides in-
ducing the formation of protein cross-links, AGEs may also bind to cell 
membrane receptors and elicit intracellular damage. Interaction of AGEs with 
their receptors (RAGE) on such cells as macrophages, mesangial, or endothelial 
cells initiates many of the downstream effects, including superoxide radical 
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generation and apoptosis (Nitti et al. 2005; Vincent et al. 2007) which implies 
that AGEs directly modulate and exacerbate oxidative stress in DM.  
 
 
2.4. Oxidative stress, arterial stiffness,  
and vascular protection 
Reactive oxygen species (ROS), including oxygen free radicals and its deriva-
tives are generated as by-products of normal aerobic metabolism (Pourova et al. 
2010). Tightly controlled low levels of ROS are an integral part of physiological 
processes such as signal transduction, inflammatory response, phagocytosis, 
cellular growth and differentiation, apoptosis, and aging (Thannickal and 
Fanburg 2000). Due to their unpaired electron, they are highly reactive and may 
damage lipids, proteins, and DNA (Freeman and Crapo 1982). A network of 
intra- and extracellular antioxidants mediates the protection against potential 
damaging effects by ROS. The imbalance between the production of ROS and 
antioxidant defence may be defined as OxS. Prolonged excessive production of 
ROS and other reactive species, resulting in high-grade OxS, has been 
implicated in the pathogenesis of several CV diseases, including atherosclerosis, 
hypertension, and heart failure (Cai and Harrison 2000; Kals et al. 2006b). In 
the vasculature, high-grade OxS plays an important role in the deterioration of 
endothelial function, most importantly by disturbing the endothelium-dependent 
vasorelaxation and vascular remodelling (Drexler and Hornig 1999; Fortuno et 




2.4.1. Oxidative stress, vitamin D, and diabetes mellitus 
Hyperglycaemia-induced high-grade OxS has been suggested as the unifying 
mechanism for the pathogenesis of diabetic complications (Brownlee 2005). 
Long-term hyperglycaemia may elevate OxS in several ways. Overproduction 
of ROS by the mitochondrial electron transport chain (Nishikawa et al. 2000), 
glucose autooxidation (Wolff and Dean 1987), and the polyol pathway (Lee et 
al. 1995) have all been described as potential sources of hyperglycaemia-driven 
OxS. Excessively produced free radicals also accelerate the formation of AGEs, 
which progressively produce more free radicals (Mullarkey et al. 1990), thus 
perpetuating the vicious cycle and leading to high-grade OxS. Although AGE 
formation is facilitated in hyperglycaemia, it has been shown that AGE levels 
were only weakly correlated with glycaemic control in the Diabetes Control and 
Complications Trial (DCCT) (Monnier et al. 1999). Furthermore, within the 
DCCT study, the AGE levels in skin were a better predictor of the development 
of complications compared to the glycated haemoglobin (HbA1c) levels 
(Monnier et al. 1999). This is consistent with the hypothesis that other factors 
such as OxS may significantly contribute to the production and accumulation of 
AGEs regardless of good glycaemic control (Baynes 1991).  
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Achieving euglycaemia in patients with DM is a difficult task despite 
examples set by large-scale studies such as the DCCT or the United Kingdom 
Prospective Diabetes Study (Stratton et al. 2000). Therefore, therapies speci-
fically targeted at preventing vascular complications in the presence of 
suboptimal control of hyperglycaemia are needed. Because of their central role 
in the development of diabetic complications, interventions aimed at reducing 
the accumulation of AGEs may provide significant improvement of DM-
induced vascular disease. These strategies may be situated in different steps of 
AGE formation and AGE-mediated damage. From a practical point of view, the 
drugs can be distinguished as: 1) AGE inhibitors or AGE cross-link breakers; 2) 
RAGE signalling blockers; 3) other compounds possessing AGE inhibitor 
activity, including antioxidants and anti-inflammatory drugs. Due to hetero-
geneity of AGEs and their diverse distribution in tissues, there is no consensus 
on which therapeutic strategies would be most relevant regarding AGE inhi-
bition in addition to the maintenance of adequate glycaemic control. Beneficial 
effects on arterial function and structure have been reported with a number of 
agents that are known to reduce AGE accumulation, including aminoguanidine 
(Brownlee et al. 1986), alagebrium (Vaitkevicius et al. 2001), RAS inhibitors 
(Monacelli et al. 2006; Saisho et al. 2006), vitamin B compounds (Stirban et al. 
2006), and peroxisome proliferator-activated receptor (PPAR) activators (Wang 
et al. 2006). 
Most of the AGE inhibitors listed above have also exhibited favourable 
effects on excess ROS generation within tissues. Furthermore, antioxidants and 
free radical trapping agents, including carnosine (Hipkiss and Chana 1998), 
benfotiamine (Babaei-Jadidi et al. 2003), pyridoxamine (Jain and Lim 2001), 
and curcumin (Sajithlal et al. 1998) have been reported to inhibit the formation 
of AGE-crosslinks or decrease tissue AGE levels. Increasing body of evidence 
suggests a role for vitamin D signalling pathways in redox homeostasis. 
Vitamin D has been reported to act as a membrane antioxidant by inhibiting 
lipid peroxidation in vitro (Wiseman 1993) and maintain a steady level of 
glutathione (GSH), a potent intracellular antioxidant, in rat hepatocytes in vivo 
(Sardar et al. 1996). In haemodialysis patients, vitamin D deficiency has been 
associated with elevated levels of malondialdehyde, nitrites, and carbonyl 
groups, that were improved by treatment with paricalcitol, a vitamin D analogue 
(Izquierdo et al. 2012). Vitamin D deficiency in asymptomatic subjects has 
been associated with high levels of thiobarbituric acid reactive substances, 
indicating lipid peroxidation, that were significantly decreased after vitamin D 
replacement (Tarcin et al. 2009). Experimentally induced vitamin D deficiency 
in healthy rats has been shown to increase BP and promote superoxide 
generation in the aortic wall (Argacha et al. 2011). However, the role of vitamin 
D as a potential antioxidant in different pathological conditions has not been 
fully investigated. In view of the beneficial effects of vitamin D on CV health, 
we have examined the potential impact of vitamin D supplementation on OxS 
and antioxidant defence in a rat model of STZ-induced DM (Paper III). 
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2.3.2. Renin-angiotensin system and  
vascular protection in diabetes mellitus 
The renin-angiotensin system plays an important role in the regulation of 
arterial structure and function. Angiotensin II (Ang II) has powerful vaso-
constrictive properties that are important for the regulation of BP (Dzau et al. 
1991). However, it also contributes to vascular wall remodelling via non-
haemodynamic mechanisms such as stimulation of VSM proliferation and re-
arrangement of elastin and collagen fibres (Griffin et al. 1991). Hyperglycaemia 
enhances the production of Ang II in the vascular tissue (Miller 1999) pro-
moting vascular hypertrophy and wall stiffness. Blockade of RAS with either 
ACEIs or ARBs has been reported to improve CV outcomes and reduce the risk 
of micro- and macrovascular complications of DM (UK Prospective Diabetes 
Study Group 1998; Heart Outcomes Prevention Evaluation Study Investigators 
2000; Brenner et al. 2001). Furthermore, clinical studies have demonstrated that 
while RAS blockers are equally effective in BP reduction they may be superior 
to other antihypertensive agents in reducing the risk of CV events in patients 
with DM (Lindholm et al. 2002). It is suggested that the favourable influence of 
RAS blockers on the vasculature are, at least in part, due to reduction in the 
adaptive remodelling and stiffening of the arterial wall independently on their 
BP lowering effects.  
Among ARBs, telmisartan has exhibited beneficial metabolic effects by 
increasing insulin sensitivity (Pershadsingh and Kurtz 2004) and improving 
plasma lipid profile (Derosa et al. 2004). Telmisartan has been reported to act as 
a partial agonist of PPAR-γ (Benson et al. 2004), which is involved in the regu-
lation of carbohydrate and lipid metabolism (Takano et al. 2004). Furthermore, 
there is increasing evidence that PPAR-γ agonists exert anti-inflammatory, anti-
oxidative, and antiproliferative effects on the vascular wall (Takano et al. 2004; 
Marx et al. 2004). Collectively, these properties indicate that telmisartan may 
provide unique possibilities for the prevention and treatment of DM and its 
vascular complications. We aimed to assess the antiproliferative effect of 
telmisartan within the diabetic aortic wall and hypothesised that this would be 
associated with reduction in aortic stiffness independently on BP (Paper II). 
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3. AIMS OF THE STUDY 
The general aim of the study was to investigate the impact of vitamin D on the 
structural, functional, and biochemical parameters of the aortic wall, and on 
oxidative stress at a systemic and target organ level, as well as to study the 
effect of an angiotensin II receptor blocker telmisartan on arterial damage as-
sociated with experimental diabetes mellitus. 
 
The specific aims of the study were as follows: 
1.  To assess aortic stiffness, as measured by aortic pulse wave velocity, in a rat 
model of streptozotocin-induced type 1 diabetes mellitus (STZ-T1DM). 
2.  To investigate the morphometric parameters in the histological preparations 
of the aorta and advanced glycation end-products in the aortic wall in STZ-
T1DM. 
3.  To measure the serum levels of asymmetric dimethylarginine and assess 
oxidative stress level and total antioxidant capacity in the serum and liver in 
rats with STZ-T1DM. 
4.  To investigate the effects of treatment with vitamin D on aortic stiffness and 
aortic remodelling, oxidative stress level, and advanced glycation end-
products in rats with STZ-T1DM. 
5.  To investigate the effects of treatment with telmisartan, an angiotensin II 
receptor blocker, on aortic stiffness and aortic remodelling in rats with STZ-
T1DM. 
6.  To assess the relationship between aortic pulse wave velocity and vitamin D, 
and markers of inflammation, in young well-trained men exposed to long-
term physical and environmental stress. 
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4. MATERIALS AND METHODS 
4.1. Experimental animals 
Male Wistar rats (RccHan:WIST, age 4 months, n=30 [Paper I], age 3 weeks, 
n=40 [Paper II]) were purchased from Harlan Laboratories (Harlan Laboratories 
Inc., The Netherlands). The animals were kept in a room with controlled 
temperature (21 ± 2 °C) and lighting (12:12-h light-dark cycle) with free access 
to food pellets and tap water. The animals were allowed to acclimatise for at 
least one week in the animal colony before entering experiments. All experi-
mental procedures were approved by the Estonian National Board of Animal 
Experiments and were conducted in accordance with the European Commu-
nities Directive (86/609/EEC). 
 
 
4.2. Study subjects 
A total of 65 well-trained male soldiers (age 26 ± 4 years) from the Estonian 
ESTCOY-8 infantry company were examined before and after a 6-month 
military mission in Afghanistan. Pre-deployment measurements were performed 
two weeks before the company’s deployment. Post-deployment measurements 
took place within one week after the return from Afghanistan. None of the 
participants showed any signs or symptoms of CVD (based upon history, 
electrocardiography, and exercise test), infection, or inflammatory disorders. 




4.3.1. Experimental protocol 
4.3.1.1. Vitamin D experiment 
Rats were randomly assigned to three groups of equal size: control group, dia-
betic group, and cholecalciferol-treated diabetic group (Papers I and III). Dia-
betes mellitus was induced by a single intraperitoneal injection of STZ  
50 mg/kg (Sigma-Aldrich, St. Louis, MO, USA) freshly dissolved in 0.9% NaCl 
solution. Blood samples were taken 48 h later from the tail vein and glucose 
levels were measured with a glucometer (Glucocard X-meter, Arkray Inc., 
Japan). Diabetes was determined by blood glucose levels >15 mmol/L. 
Immediately after confirmation of diabetes, one diabetic group of animals was 
submitted to supplementation with cholecalciferol (Sigma-Aldrich, St. Louis, 
MO, USA) 12.5 µg (500 IU) kg-1 body weight, dissolved in 0.3 mL olive oil 
administered orally. Cholecalciferol was administered every other day by 
gavage for a period of 10 weeks. Weekly, body weights were monitored and 
glycosuria was assessed with reagent strips (Combur Test, Roche, Germany) to 
exclude ketosis. Haemodynamic measurements were performed 10 weeks after 
the DM induction. 
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4.3.1.2. Telmisartan experiment 
Rats were randomly assigned to three groups: control (n=10), untreated diabetic 
(n=15), and telmisartan-treated diabetic (n=15) group (Paper II). Intraperitoneal 
injection of STZ 65 mg/kg (Sigma-Aldrich, St. Louis, MO, USA), freshly 
dissolved in 0.9% saline, was used to induce DM. After 48 hours, blood glucose 
was measured in samples taken from the tail vein, using a glucometer (Gluco-
card X-meter, Arkray Inc., Japan). Rats were considered diabetic if the blood 
glucose was >15 mmol/L. Treatment with telmisartan (Boehringer Ingelheim 
International GmbH, Germany) was started immediately after confirmation of 
DM. Telmisartan (10 mg/kg per day) was administered by gavage, dissolved in 
drinking water, for 10 weeks. Telmisartan was stopped one day prior to mea-
surement of haemodynamic parameters. Weekly, body weights were recorded 
for all groups and glycosuria was assessed with reagent strips (Combur Test, 
Roche, Germany) to exclude ketosis in rats with DM. 
 
 
4.3.2. Study protocol 
The soldiers completed a questionnaire concerning their personal and familial 
medical history, lifestyle, physical activity/training habits, and basic demo-
graphic data. The participants were studied and blood samples were obtained 
following an overnight fast and abstinence from any medication, tobacco, 
alcohol, tea, and coffee. After 10 minutes of rest in the supine position BP was 
measured, pulse wave analysis (PWA) was performed, and aortic PWV was 
measured in all subjects. Venous blood samples were collected from the ante-
cubital fossa. Height and weight of the soldiers were recorded and body mass 
index was calculated. 
Informed written consent was obtained from each soldier in accordance with 
principles of the Declaration of Helsinki. The study protocol was approved by 
the Ethics Committee, University of Tartu, Estonia. 
 
 
4.3.3. In vivo haemodynamic measurements 
4.3.3.1. Induction of anaesthesia 
The animals were anaesthetised with a mixture of fentanyl (0.07 mg/kg, 
Gedeon-Richter Plc., Hungary), midazolam (5 mg/kg, Roche Pharma AG, Ger-
many), and ketamine (75 mg/kg Vetoquinol Biowet Sp. z.o.o., Poland) admi-
nistered subcutaneously. The optimal concentrations of the anaesthetic substan-
ces had been determined in pilot experiments. The depth of anaesthesia was 
monitored regularly by assessing the reflex response to noxious stimuli (hind-
paw pinch) or tactile stimuli (corneal stroking). After induction of anaesthesia, 




4.3.3.2. Measurement of pulse wave velocity 
A 2.5 F high-fidelity dual pressure sensor catheter with 50 mm separation 
between sensors (SPC-721, Millar Instruments Inc., TX, USA) was soaked in a 
water bath for 30 minutes to allow stability of the baseline before balancing and 
calibration against a mercury sphygmomanometer. The catheter was then intro-
duced via the femoral artery into the descending aortic trunk so that the distal 
sensor was positioned at the beginning of the descending aorta and the resulting 
position of the proximal sensor was just proximal to the aortic bifurcation. The 
positioning of the distal sensor in the thoracic aorta was confirmed by the 
appearance of the incisura on the pressure waveform, indicating the aortic valve 
closure. 
The rats were allowed to stabilise before resting blood pressures were 
recorded. Pulse pressure waves were recorded simultaneously at the two aortic 
sites and PWV was calculated offline by dividing the propagation distance by 
propagation time using an automated foot-to-foot method (Nichols and 
O’Rourke 2005; Mitchell et al. 1997). Data were acquired at a sampling rate of 
2 kHz (PowerLab, ADInstruments, Australia) and feature extraction and calcu-
lations made with custom scripts in Spike2 v.6. software (Cambridge Electronic 
Design, United Kingdom).  
 
 
4.3.3.3. Administration of vasoactive substances 
Mean arterial pressure (MAP) was increased and decreased by infusion of PE 
(50 µg/min) and NTG (30 µg/min), respectively, via a catheter inserted into the 
femoral vein. Each drug was infused until the BP plateaued. Between the 
infusions, the rats were allowed a stabilisation period of at least 5 minutes and 
subsequent infusion of the opposing substance was given after the BP had 
returned to baseline. For PWV calculations, the range of pressure pulses during 
the decreasing MAP segment was selected after PE infusion, while the range of 
pressure pulses during the increasing MAP segment was selected after NTG 
infusion. These pressure ranges were assumed to be unaffected by the direct 
action of the vasoactive substances on the arterial function. 
 After the haemodynamic measurements were completed, blood samples 
were taken from the tail vein for assessment of glucose levels with a glucometer 
(Glucocard X-meter, Arkray Inc., Japan) [Paper I]. The rats were euthanised by 
drawing blood by cardiac puncture, followed by cervical dislocation. Samples 
of liver and aortic tissue were collected, soaked in ice-cold 0.9% NaCl, snap-
frozen in liquid nitrogen, and stored at –60 ºC until use [Paper III]. Urine 
samples were obtained, drawn directly from the urinary bladder, and stored  




4.3.3.4. Haemodynamic data extraction 
Simultaneous recording of multiple haemodynamic parameters enabled to ana-
lyse the relationship of BP and PWV on a pulse-by-pulse basis (Figure 3). The 
proximal arterial pressure waveform was used to construct a QRS complex in 
the electrocardiogram (ECG) waveform for calculation of heart rate (HR). The 
peak of the first derivative of the pressure waveform was used for calculations. 
The period of the waveform defined the R to R interval and the inverse of the 
period was output as a measure of HR. 
Throughout the experiment, systolic blood pressure (SBP), diastolic blood 
pressure (DBP), pulse pressure (PP), and MAP were determined from measure-
ments made by the proximal pressure sensor in the abdominal aorta. 
An algorithm designed and rigorously tested in previous studies (Butlin 
2007) was employed to calculate PWV across a range of different pressure 
waveform shapes (Figure 4). Briefly, this algorithm of pressure foot location 
relies solely on the early segment of the systolic upstroke of the pressure 
waveform. The early systolic upstroke is not subject to the variability of late 
diastole, and is assumed to be free from augmentation by the reflected pressure 
wave (Nichols and O'Rourke 2005; Nitta et al. 2004). Using this algorithm, the 
foot of the pressure wave was defined by the peak of the second time derivative 
of pressure during each pulse (Chiu et al. 1991; Hermeling et al. 2007). 
Pulse wave velocity was then plotted against MAP to construct phase plots 
to be used to characterise the PWV over a range of MAP from 50 to 200 mmHg 
in the aorta. Isobaric PWV indicates the comparison of PWV measured during 
the experiment at similar levels of BP when and compared among groups. This 
method for in vivo measurement of aortic BP and pulse-by-pulse pressure-
dependent PWV has been employed in recent studies (Ng et al. 2011; Ng et al. 







































































































































































































































































































































































































































































































































































































































































































































































































































































































4.3.4. Haemodynamic measurements in human subjects 
4.3.4.1. Measurement of blood pressure 
Peripheral BP was measured in the dominant arm using a validated oscillo-
metric technique (OMRON M4-I, Omron Healthcare Europe, The Netherlands). 
Mean arterial pressure was obtained by integration of the radial pressure 
waveform using the Sphygmocor device with accordant software (SCOR Px, 
version 7.0; AtCor Medical, Australia). Peripheral PP was calculated as the 
difference between peripheral SBP and peripheral DBP. All measurements of 
BP were made in duplicate and mean values were used in subsequent analysis. 
 
 
4.3.4.2. Aortic pulse wave velocity 
Pulse wave velocity was measured by the foot-to-foot method using a Sphyg-
mocor device. Pulse wave velocity was determined by sequentially recording 
ECG-gated carotid and femoral artery waveforms using a Millar tonometer 
(SPT-301B, Millar Instruments, TX, USA). Wave transit time was calculated as 
the time delay between the arrival of the pulse wave at the common carotid 
artery and the common femoral artery using the R wave of a simultaneously 
recorded ECG as the reference frame. The surface distance between the two 
recording sites was measured as the distance from the suprasternal notch to the 
common femoral artery minus the distance from the suprasternal notch to the 
common carotid artery. The difference between the carotid and the femoral path 
lengths was estimated from the distance of the sternal notch to the femoral pulse 
measured in a direct line. All measurements were made in duplicate and mean 
values were used in subsequent analysis. 
 
 
4.3.4.3. Pulse wave analysis 
Radial artery pressure waveforms were recorded with a high-fidelity appla-
nation tonometer (SPT-301B, Millar Instruments, TX, USA) on the wrist of the 
left hand. After 20 sequential waveforms had been acquired, the integral soft-
ware (SCOR Px, version 7.0; AtCor Medical, Australia) was used to generate a 
corresponding central (ascending aortic) waveform by a generalized transfer 
function, which has been prospectively validated for assessment of central BP 
(Sharman et al. 2006). Augmentation index, central SBP, central DBP, and 
central PP were derived from PWA. Augmentation index was calculated as the 
difference between the second and the first systolic peaks and expressed as the 
percentage of central PP (Wilkinson et al. 1998). Augmentation index was 





4.3.5. Laboratory analyses 
Leukocyte and platelet counts were assessed in whole blood using a QBC 
Autoread Plus autoanalyser (QBC Diagnostics, Inc., USA) (Paper IV). For other 
tests the blood samples were centrifuged within 15 minutes after collection at 
3000 rpm for 15 minutes to obtain serum that was frozen at –60 °C until further 
analysis (Papers I–IV). Plasma glucose, total cholesterol, low-density lipopro-
tein, high-density lipoprotein, and triglycerides were determined by standard la-
boratory methods, using certified assays, in a local clinical laboratory (Paper 
IV).  
 
4.3.5.1. Biomarkers of inflammation 
The plasma level of high-sensitivity CRP was measured by a validated latex 
particle-enhanced high-sensitivity immunoturbidimetric assay (CRP [Latex] 
HS, Roche Diagnostics Gmbh®, Mannheim, Germany), and analysed by the 
Hitachi 912 analyser (Roche Diagnostics®, Basel, Switzerland) (Paper IV). 
 Interleukin-1α, interleukin-2, interleukin-4, interleukin-6, interleukin-10, 
tumour necrosis factor alpha, interferon gamma, and monocyte chemoattractant 
protein-1were analysed with the Cytokine and Growth Factors High-sensitivity 
Array of the automated biochip immunoassay system, Evidence Investigator™ 
(Randox Laboratories Ltd., United Kingdom) (Paper IV). 
 
 
4.3.5.2. Serum level of 25-hydroxyvitamin D 
Serum 25(OH)D level was measured using a radioimmune assay (25-
Hydroxyvitamin D, 125I Ria Kit, DiaSorin Corporation, MN, USA) (Papers I 
and IV). This assay has shown good correlation (r=0.74 to 0.96) with the liquid 
chromatography-tandem mass spectrometry that is currently regarded as the 
gold standard for the assessment of 25(OH)D (Zerwekh 2008). The assay 
consisted of two steps. The first step involved an extraction of 25(OH)D from 
serum with acetonitrile. The extraction was followed by competitive radio-
immune assay using 125I-labelled 25(OH)D and antibody to 25(OH)D. The 
sample, antibody, and tracer were incubated for 90 minutes. Phase separation 
was accomplished after 20-minute incubation with a second antibody pre-
cipitating complex. Then a buffer was added to reduce non-specific binding. 
This was followed by centrifugation. Intra-assay and inter-assay coefficients of 
variation were 8.1% and 10.2%, respectively. 
 
 
4.3.5.3. Serum levels of calcium and albumin 
Calcium concentration in the serum was determined by a colorimetric test 
(Calcium liquicolor, HUMAN Gesellschaft für Biochemica und Diagnostica 
mbH, Germany) (Papers I and III). This assay is based on the reaction between 
calcium ions and o-cresolphthalein-complexone in an alkaline medium, 
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resulting in a purple coloured complex. The absorbance of this complex was 
measured spectrophotometrically at 570 nm using a photometer (Tecan Sunrise, 
Tecan GmbH, Austria). 
Serum albumin levels were measured using a colorimetric test (Albumin 
liquicolor, HUMAN Gesellschaft für Biochemica und Diagnostica mbH, 
Germany) (Paper II). In this assay, bromocresol green forms with albumin in 
citrate buffer a coloured complex. The absorbance of this complex was 
measured spectrophotometrically at 578 nm. Serum calcium levels were 
corrected for albumin concentrations using the following formula: corrected 
calcium = serum calcium + 0.02 × (40 – serum albumin) (Gardner et al. 1981). 
 
 
4.3.5.4. Glucose level in urine 
Glucose concentration in the urine samples was measured by a colorimetric 
hexokinase glucose-6-phosphate dehydrogenase method (Glucose-HK kit, 
Spinreact, Spain) (Paper II). Hexokinase catalyses the adenosine triphosphate 
(ATP)-dependent phosphorylation of glucose to glucose-6-phosphate. The 
formed glucose-6-phosphate is reduced to 6-phosphogluconate in the presence 
of glucose-6-phosphate dehydrogenase with the subsequent reduction of 
nicotinamide adenine dinucleotide (NAD) to reduced nicotinamide adenine 
dinucleotide (NADH). The increase in the concentration of NADH, measured 
spectrophotometrically at 340 nm, is proportional to the glucose concentration 
in the sample. 
 
 
4.3.5.5. Serum level of asymmetric dimethylarginine 
Asymmetric dimethylarginine was determined from serum samples by an 
enzyme-linked immunosorbent assay (ELISA) using a commercial kit (DLD 
Diagnostika, Germany) (Paper I). ADMA is bound to the solid phase of the 
microtitre plate. In samples ADMA is acylated and competes with the solid 
phase-bound ADMA for a fixed number of rabbit anti-ADMA anti-serum 
binding sites. At equilibrium, free antigen and free antigen-antiserum 
complexes are removed by washing. The antibody bound to the solid phase 
ADMA is detected by anti-rabbit/peroxidase. The substrate tetra-methyl-
benzidine (TMB)/peroxidase reaction is analysed spectrophotometrically at  




4.3.5.6. Measurement of total antioxidant capacity  
in the serum and liver 
Liver samples were homogenised in ice-cold 0.9% NaCl solution and 
centrifuged at 15,000 x g for 10 minutes at 4ºC (Paper III). The insoluble pellets 
were discarded and the supernatants were used for analysis. An automated 
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colorimetric measurement method was employed (Erel 2004) using a colori-
metric assay (Randox Laboratories Ltd., United Kingdom). By this method, a 
colourless molecule, reduced 2,2'-azinobis(3-ethylbenzthiazoline-6-sulphonate) 
(ABTS), is oxidised to a blue-green ABTS*+, using hydrogen peroxide in aci-
dic medium (the acetate buffer 30 mL/L pH 3.6). When the coloured ABTS*+ 
is mixed with any substance that can be oxidized, it is reduced to its original 
colourless ABTS form again. The 2,2'-azinobis(3-ethylbenzthiazoline-6-
sulphonate)*+ is decolourised by antioxidants according to their concentrations 
and antioxidant capacities. This change of colour is measured as a change in 
absorbance at 660 nm. 
Briefly, 200 μL of reagent 1 (R1: acetate buffer 0.4 mol/L, pH 5.8) was 
carefully mixed with 5 μL of test sample in cuvette and incubated for 4 min at 
37 °C in the spectrophotometer. The first absorbance was taken before the 
mixing with 20 μL R2 (R2: the ABTS*+ in acetate buffer 30 mmol/L, pH 3.6 
[as sample blank]). The last absorbance was taken at the end of incubation  
(5 min). The bleaching rate is inversely related with the total antioxidant 
capacity (TAC) of sample. The reaction rate was calibrated with Trolox, which 
is used as a traditional standard for TAC measurement assays. The results are 
expressed in mmol Trolox equivalent/L. The data for the liver samples were 
expressed as mmol Trolox equivalent/mg protein with protein concentration 
measured spectrophotometrically using the Lowry method (Lowry et al. 1951). 
Within- and between-batch precision data obtained by TAC method were 2.5 
and 2.9% respectively. 
 
 
4.3.5.7. Measurement of total peroxide concentrations and  
oxidative stress index in the liver 
Liver samples were homogenised in ice-cold 0.9% NaCl solution and centri-
fuged at 15,000 x g for 10 minutes at 4ºC (Paper III). The insoluble pellets were 
discarded and the supernatants were used for analysis. Total peroxide con-
centrations (TPX) were measured with an OxyStat colorimetric assay kit (Bio-
medica Gruppe, Austria). Total peroxide concentration is determined by 
reaction of the biological peroxides with the enzyme peroxidase and a sub-
sequent colour-reaction using TMB as substrate. After adding the stop solution 
the developed colour is measured spectrophotometrically at 450 nm. A calib-
rator is measured in parallel and used to calculate the concentration of 
circulating biological peroxides in the sample in a one-point calibration proto-
col. The results show a direct correlation between free radicals and circulating 
biological peroxides, and thus allow the characterisation of the oxidative status 
in biological samples. The detection limit of the assay is 7 µmol/L. The intra-
assay and inter-assay coefficients of variation were 3.1% and 5.1%, respecti-
vely. The data were expressed as nmol/mg protein, with protein concentration 
measured spectrophotometrically using the Lowry method (Lowry et al. 1951). 
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Oxidative stress index (OSI) was expressed as per cent ratio of TPX level to 
TAC level (Harma et al. 2003). For calculation purposes, the resulting unit of 
TAC, mmol/L, was changed to μmol/L, and the OSI value was calculated ac-
cording to the following formula: OSI = TPX (μmol/L) / TAC (μmol/L) × 100. 
 
 
4.3.5.8. Measurement of Nε-(carboxymethyl)lysine levels  
in the aortic wall 
Aortic strips (10 mm) were homogenised in ice-cold 0.9% NaCl solution, using 
a blade type homogeniser (Tekmar Tissumizer, Cincinnati, OH, USA) and 
centrifuged at 10,000 x g for 10 minutes at 4ºC (Paper III). The insoluble pellets 
were discarded and the supernatants were used for analysis. The concentration 
of CML was assessed using a commercial ELISA test OxiSelect™ N-epsilon-
(Carboxymethyl) Lysine ELISA Kit (Cell Biolabs, Inc., San Diego, CA, USA). 
Ten µg/ml of total protein extracts were adsorbed onto a 96-well plate at 4ºC 
overnight, with protein concentration measured spectrophotometrically using 
the Lowry method (Lowry et al. 1951). The absorbance of each well was mea-
sured spectrophotometrically at 450 nm. The concentration of CML was 
calculated by comparison to a standard curve consisting of known concentra-
tions of CML-BSA (bovine serum albumin). Results are presented as nanogram 
of CML per milliliter of solution. 
 
 
4.3.6. Histological analysis of the aorta 
4.3.6.1. Assessment of wall structure and morphometric parameters 
The aortic samples for histological analysis were fixed in 10% formalin for  
12 hours and embedded in paraffin with vacuum infiltration processor (Tissue-
Tek® VIPTM 5 Jr, Sakura, USA) (Papers I and II). Specimens were cut with 
microtome Ergostar HM 200 (Microm, Germany) at four-µm thickness sections 
and stained using the haematoxylin-eosin, resorcin-fuchsin, and van Gieson 
methods for examination by light microscopy (Olympus BX50, Japan).  
Estimation of the internal diameter of the aorta was performed by measuring 
two inner diameters at right angle for each cross-section of the thoracic aorta. At 
least eight different cross-sections of the aorta were analysed for each rat.  
Thickness of the medial layer of the aorta was determined in the thoracic 
aorta cross-sections by ten consecutive measurements in a systematic manner to 
evaluate all segments of the circumference of the aorta. At least six different 
cross-sections of aorta were analysed for each rat. The staining intensities of the 
elastic fibres in the media and collagen fibres in the media and adventitia were 
evaluated on a subjective scale ranging from 0 to 3 (0 – no staining of fibres, 1 – 
poor staining of fibres, 2 – moderate staining of fibres, 3 – intensive staining of 
fibres). The evaluations were performed by two independent observers in a 
blinded fashion; the scores were summed and used for statistical analysis.  
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4.3.6.2. Immunohistochemical assessment  
of Nε-(carboxymethyl)lysine in the aortic wall 
Three-µm thick paraffin sections mounted on poly-L-lysine coated SuperFrost 
slides (Menzel Gläser, Germany) were deparaffinised and rehydrated (Paper 
III). Peroxidase activity was blocked by 0.6% H2O2 (Merck, Germany) in 
methanol (Merck, Germany). Then the sections were washed in tap water and in 
phosphate buffered saline (pH = 7.4; Gibco, Invitrogen, CA, USA) for  
10 minutes, treated with normal 1.5% goat serum (Gibco, Invitrogen Corpo-
ration, CA, USA) for 20 minutes at room temperature and incubated with the 
first antibody: anti-CML (mouse monoclonal antibody [CML26], abcam, 
United Kingdom) diluted 1:50 overnight at 4C in the humidity chamber. On 
the next day the sections were incubated with the biotinylated horse anti-mouse 
secondary antibody for 30 min at room temperature. After a wash step the 
sections were incubated with the avidin-biotin peroxidase complex ELITE 
system (Vectastain Elite ABC Kit, Vector Laboratories Inc., Burlingame, CA, 
USA) for 30 minutes. Peroxidatic activity was detected with 3,3'-diamino-
benzidine (Vector Laboratories Inc., USA) and the sections were counterstained 
with hemalaun, dehydrated, and mounted with DPX (Fluka, Switzerland). The 
labelling was expressed on a semi-quantitative scale ranging from 0 to 4 (0 – no 
staining, 1 – weak staining, 2 – moderate staining, 3 – strong staining, 4 – very 
strong staining). Two independent observers in a blinded fashion performed the 
evaluation. Immunohistochemistry negative controls were performed by 




4.3.7. Statistical analysis 
Statistical comparisons were performed with the Statistica software (version 8; 
StatSoft, USA) (Papers I-IV) and with the software R (version 2.15.3 for 
Windows; The R Foundation for Statistical Computing, Austria) (Paper II). 
Continuous variables are shown as mean ± standard deviation or medians with 
interquartile ranges. All data were tested for normality using the Kolmogorov-
Smirnov test (Papers I–IV). 
 In Paper II, all haemodynamic parameters were averaged into 5 mmHg MAP 
bins. Analysis was restricted to the MAP range of 60 to 185 mmHg. Rat S11 
and S12 were merged to create one sample, due to lack of data in each rat. Rat 
S14 was removed due to lack of data. Second order polynomials were fitted 
using least squares regression to each individual rat data set, a second order 
polynomial being confirmed as a better fit than either linear or third order 
polynomial by Akaike Information Criterion (Table 1) (Akaike 1974). The 
intercepts (a) and coefficients (b, c) were extracted from the polynomial model 
(Equation 1), and comparison between groups made by analysis of variance 
(ANOVA), using a post-hoc, Bonferroni corrected t-tests to ascertain diffe-
rences. 
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For analysis of the data as a whole, one of two methods was employed. (1) 
The data was transformed into a linear form (Equation 2) and analysis of 
covariance (ANCOVA) was employed if the assumption of equal slopes was 
maintained. (2) If the assumption of equal slopes was not maintained, robust 
analysis ANCOVA (Wilcox 2005) was employed with comparison of groups at 
60, 90, 120, 150, and 180 mmHg MAP and a 20% trimmed mean. The robust 
analysis ANCOVA accommodates non-linearity, heteroscedasticity, and un-
equal slopes. The assumption of equal slopes was tested by ANCOVA as in 
method (1) with an interaction term between PWV and MAP, and PWV and 
MAP2. If either interaction was significant, showing that slopes were not equal, 
method (2) was employed. 
 
Equation 1     = + × + × 2 
 
Equation 2     2 =  
 
Differences in resting haemodynamic variables and basic and laboratory para-
meters between the groups were evaluated using the one-way ANOVA followed 
by Tukey’s post-hoc analysis for multiple comparisons of group means. (Papers 
I–III). Semi-quantitative data were compared by the Kruskal-Wallis one-way 
ANOVA followed by Mann-Whitney U test (Papers I–III). 
Skewed variables were log-transformed before the analysis to obtain a 
normal distribution (Paper IV). Comparisons of two different groups were per-
formed using the unpaired t-test (Paper IV). The Pearson correlation analysis 
was used to examine the associations between the parameters (Paper IV). 
Statistical significance was defined as P <0.05 (Papers I–IV). 
 
 
Table 1. Model 1: linear; Model 2: second order polynomial; Model 3: third order poly-
nomial fit. A second order polynomial provides the best fit to the grouped data. 
 
 Df      AIC 
Model 1 5.00    970.37 
Model 2 6.00    786.11 
Model 3 7.00    787.55 
 






5.1. Aortic stiffening and remodelling  
in experimental diabetes (Papers I and II) 
5.1.1. Basic and biochemical characteristics 
5.1.1.1. Vitamin D experiment 
The results are presented in Table 2. The initial body weights were similar in 
control and diabetic groups. The final body weights in the diabetic groups were 
significantly lower than in the control group. The levels of blood glucose and 
HbA1c were found to be significantly increased in the diabetic rats. Serum 
25(OH)D levels were significantly decreased in the untreated diabetic group, 
compared to the control group. Serum levels of ADMA were significantly lower 
in the control group compared with untreated diabetic group. 
  
 
5.1.1.2. Telmisartan experiment 
The initial body weights were similar in all groups (Table 3). In the course of 
the experiment, rats in both treated and untreated diabetic groups presented with 
abnormalities associated with persistent hyperglycaemia: hyperphagia, poly-
dipsia, polyuria, and wasting of stored fat as evidenced by retarded weight gain. 
The final body weights were significantly lower in diabetic groups compared to 
the control group, while no difference was found between the treated and 
untreated diabetic groups. The ratio of heart weight to body weight as a 
surrogate index of cardiac hypertrophy was significantly increased in both 
diabetic groups, compared to the control group. Glucose concentration in the 
urine samples was significantly higher in both diabetic groups, compared to the 
control group. Treatment with telmisartan resulted in slight but statistically 







































































































































































































































































































































































































































   








   
   
   
   


































































































































































































































5.1.2. Haemodynamic parameters 
5.1.2.1. Vitamin D experiment 
Before administration of vasoactive substances, resting SBP, DBP, PP, MAP, and 
HR were not statistically different between all groups (Table 4). Intravenous 
infusion of PE increased MAP to 200 mmHg, followed by infusion of NTG, 
which decreased MAP to 50 mmHg. The diabetic rats had a significantly higher 
PWV compared to the control rats across a supraphysiological range of MAP 
(170–200 mmHg), but not at a lower MAP range. The non-linear PWV-MAP 
curve for the diabetic treated group was similar to that of diabetic untreated 
group, indicating that aortic stiffness was similar at every given MAP (Figure 5). 
 
 
Table 4. Resting anaesthetised haemodynamic parameters obtained before the administ-














Control 140 ± 30 106 ± 27 118 ± 28 34 ± 6 364 ± 96 5.0 ± 0.6 
Diabetes 135 ± 15 103 ± 18 114 ± 17 31 ± 4 343 ± 53 5.2 ± 0.3 
Diabetes + 
vitamin D 
136 ± 14 104 ± 12 115 ± 12 32 ± 3   348 ± 107  4.9 ± 0.3 
 
SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial pres-
sure; PP, pulse pressure; HR, heart rate; PWV, pulse wave velocity.  




Figure 5. Isobaric PWV-MAP curves in the control, untreated diabetic, and diabetes + 
vitamin D groups, averaged over 5 mmHg pressure steps. * P <0.05 vs Control.  
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5.1.2.2. Telmisartan experiment 
Prior to administration of vasoactive substances, SBP, DBP, PP, MAP, HR, 
PWV, and maximal change in BP (dP/dt) were recorded (Table 5). There were 
no differences in BPs between the control and untreated diabetic group. HR was 
significantly decreased in the untreated diabetic group, compared to the control 
group. Peak dP/dt, a surrogate index of systolic function, was significantly 
decreased in the untreated diabetic rats.  
The means and standard deviations of coefficients of the second order poly-
nomial curve fits to individual rats in = + × + × 2 are 
provided in Table 6. Analysis of variance on the intercepts and coefficients is 
provided in Tables 7, 9, and 11. There was no significant difference in the inter-
cept (a) between the groups, but there was a significant difference in the 
coefficients (b) and (c) between the untreated diabetics and controls (Tables 8, 
10, and 12) but not among the other groups. A second order polynomial was 
fitted on PWV-MAP curve for characterisation of pressure-independent PWV 
across the full MAP range (Figure 6). 
Table 13 gives an ANCOVA with interaction terms for MAP and Group, and 
MAP2 and Group. It shows that there was a significant interaction between 
MAP and Group (P <0.001) but not MAP2 and Group (P=0.21). As there was a 
significant interaction term, and slopes therefore unequal, robust methods 
ANCOVA was used to test between group differences. This showed differences 
between untreated diabetes and control groups at all levels other than 60, 100, 
and 110 mmHg MAP (Table 14).  
 
 
Table 5. Resting anaesthetised haemodynamic parameters obtained before the admi-








    PP 
(mmHg)
     HR 
(beats/min) 
  Peak dP/dt 
(mmHg/s) 
  PWV 
  (m/s) 
Control 155 ± 15# 113 ± 15# 130 ± 28# 41 ± 3 462 ± 46   4024 ± 617   4.5 ± 0.5# 
Diabetes 142 ± 13# 105 ± 13# 124 ± 14# 38 ± 9 386 ± 48*# 2186 ± 198*# 4.6 ± 0.9# 
Diabetes + 
telmisartan 
110 ± 14    75 ± 14  92 ± 12 35 ± 5 321 ± 26  3294 ± 183  3.6 ± 0.3 * *
 
SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial pres-
sure; PP, pulse pressure; HR, heart rate; dP/dt,  
maximal change in pressure over time;  PWV, pulse wave velocity. 





Table 6. Means and standard deviations of coefficients of the second order polynomial 
curve fits to individual rats in = + × + × 2. 
  
Group a (mean ± SD)     b (mean ± SD)         c (mean ± SD) 
Control       3.8 ± 0.9       –0.02  ± 0.02      0.00023  ± 0.00009 
Diabetes       6.0 ± 2.1       –0.07  ± 0.04      0.00045  ± 0.00018 
Diabetes + telmisartan       5.1 ± 1.5       –0.05  ± 0.03      0.00038  ± 0.00014 
 
SD, standard deviation; MAP, mean arterial pressure. 
 
 
Table 7. Analysis of variance for the intercept, (a), in 	 = + × + ×2. 
 
 Df Sum Sq Mean Sq F value P value
Group 2 21.10 10.55 4.21 0.03 
Residuals 24 60.20   2.51   
 
Df, degrees of freedom; Sum Sq, sum of squares; Mean Sq, mean of squares. 
 
 
Table 8. Bonferroni adjusted, unpaired t-test results for the intercept, (a). 
 
Group 1 Group 2 P value P adjusted 
D DT 0.34 1.00 
C DT 0.04 0.12 
C D 0.02 0.06 
 
D, Diabetes; DT, Diabetes + telmisartan; C, control. 
 
 
Table 9. Analysis of variance for the coefficient, (b), in 	 = + × + ×2. There is a significant difference in the coefficient, (b). 
 
 Df Sum Sq Mean Sq F value P value
Group 2 0.01 0.00 4.89 0.02 
Residuals 24 0.02 0.00   
 
Df, degrees of freedom; Sum Sq, sum of squares; Mean Sq, mean of squares. 
 
 
Table 10. Bonferroni adjusted, unpaired t-test results for the coefficient, (b). 
 
Group 1 Group 2 P value P adjusted
D DT 0.36 1.00 
C DT 0.03 0.08 
C D 0.01 0.04 
 
D, Diabetes; DT, Diabetes + telmisartan; C, Control. 
47 
Table 11. Analysis of variance for the coefficient, (c),  
in 	 = + × + × 2. There is a significant difference in the 
coefficient, (c). 
 
 Df Sum Sq Mean Sq F value P value
Group 2 0.00 0.00 5.48 0.01 
Residuals 24 0.00 0.00   
 
Df, degrees of freedom; Sum Sq, sum of squares; Mean Sq, mean of squares. 
 
 
Table 12. Bonferroni adjusted, unpaired t-test results for the coefficient, (c). 
 
Group 1 Group 2 P value P adjusted
D DT 0.39 1.00 
C DT 0.02 0.05 
C D 0.01 0.02 
 
D, Diabetes; DT, Diabetes + telmisartan; C, Control. 
 
 
Table 13. Analysis of covariance with an interaction term between MAP and Group, 
and MAP2 and Group. Significant interaction between Group and MAP indicates that 
the slopes of different groups are significantly different. 
 
  Df Sum Sq Mean Sq  F value      P value
MAP     1 849.91 849.91 3953.44       <0.001
MAP2     1   47.35   47.35   220.27       <0.001
Group     2   13.41     6.70     31.18       <0.001
MAP:Group     2     5.58     2.79     12.97       <0.001
MAP2:Group     2     0.67     0.34       1.56   0.2 
Residuals 571 122.75     0.21   
 
MAP, mean arterial pressure; Df, degrees of freedom; Sum Sq, sum of squares;  
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5.1.3. Histological analysis and  
morphometric parameters of the aortic wall 
5.1.3.1. Vitamin D experiment 
Aortic samples in the control group showed a regular vascular morphology, 
while several alterations were noted in the aortic wall structure in the untreated 
diabetic group. In the aortas of the untreated diabetic group focal irregular 
arrangement of elastic fibres was noted together with decreased staining inten-
sity of elastic fibres and increased internal diameter of the aorta (Table 15, 
Figures 7 and 8). Changes in the medial thickness and in collagen staining were 
not statistically significant compared to the control group (Table 3). Untreated 
DM was also associated with reduced ratio of elastin to collagen (Table 15). 
 
 
Table 15. Morphometric parameters and estimations of staining intensities of connec-
tive tissue fibres in the medial and adventitial layers of the thoracic aorta. 
 
Parameter Control Diabetes Diabetes + 
 vitamin D 
Internal diameter of aorta (mm)   1.40 ± 0.27   1.65 ± 0.18*   1.55 ± 0.21 
Thickness of media (m) 86.41 ± 8.15 79.09 ± 14.61 82.93 ± 11.29  
Elastic fibres in media (arbitrary units)   2.44 ± 0.33   1.84 ± 0.33¶;#   2.29 ± 0.26 
Collagen fibres in media (arbitrary 
units) 
  1.20 ± 0.38   1.38 ± 0.46   1.24 ± 0.41 
Collagen fibres in adventitia (arbitrary 
units) 
  2.90 ± 0.41   2.56 ± 0.40   2.52 ± 0.43 
Elastin/collagen ratio in media (%)   1.72 ± 0.55   1.33 ± 0.43*;#   1.88 ± 0.47 
 
Values are expressed as means ± SD.  





Figure 7. Micrographs of the transverse aortic sections in the control group (A), 
untreated diabetic group (B), and diabetes + vitamin D group (C). Note the enlarged 





Figure 8. A panel of micrographs of the aortic sections in the control group (A and B), 
untreated diabetic group (C and D), and diabetes + vitamin D group (E and F). 
Reduction of the thickness of the medial layer (C and D) and disorganisation of elastic 
lamellae (C) was observed in diabetic untreated rats, while in diabetes + vitamin D 
group the aortic wall morphology was more similar to the control group samples. 
Resorcin-fuchsin (A, C, E) and van Gieson (B, D, F). Original magnification ×360. 
 
 
5.1.3.2. Telmisartan experiment 
The lumen diameter of the thoracic aorta and the width of the medial layer were 
significantly smaller in the untreated diabetic group compared to the control 
group (Table 16). The staining intensity of medial elastic fibres in the untreated 
diabetic group was decreased compared to the control group (Table 16). 
Furthermore, focal irregularities in the arrangement of elastic fibres were noted 
in the untreated diabetic group (Figure 9). Even more pronounced differences 
were seen in the staining of collagen fibres in the medial layer as higher 
collagen concentrations were present in the untreated diabetes group compared 
to the control group (Table 16, Figure 9). This resulted in significantly lower 
medial ratio of elastin to collagen in the untreated diabetic group (Table 16). No 
differences between groups were seen in the count of nuclei of smooth muscle 









































   






   



















































   

















































































   












































   










































   







































































































Figure 9. Representative micrographs of the aortic walls from the control group (a and 
d), untreated diabetes group (b and e) and diabetes + telmisartan group (c and f). De-
creased thickness of the medial layer was noted in both untreated diabetes and diabetes + 
telmisartan group, while focal disorganisation of elastic lamellae were seen in untreated 
diabetes group (b). Resorcin-fuchsin (a-c) and van Gieson (d-e). 
 
 
5.1.4. Advanced glycation end-products within  
the aortic wall (Paper III) 
Untreated DM produced significantly higher levels of CML in the aortic wall 
homogenates (Figure 10). Immunohistochemical detection of CML demonstrated 
strong immunostaining in all layers of the aortic wall in the untreated diabetic 
group (Figure 11). In the control group, immunostainings were moderate in the 




Figure 10. Untreated diabetes mellitus was associated with significantly higher levels 
of Nε-(carboxymethyl)lysine in the aortic wall that was prevented by vitamin D 





















Figure 11. Immunohistochemical localisation of Nε-(carboxymethyl)lysine in the aortic 
wall of the diabetes + vitamin D group (A), untreated diabetic group (B) and control 
group (C). Strong immunostaining was found in all layers of the aorta in the diabetic 
group (B), while immunostaining in the medial layer was moderate in the diabetes + 
vitamin D group (A), similar to the staining intensity of the control group (C). Staining 
was not seen in negative controls, where the primary antibody was omitted (D). 
Diaminobenzidine + hemalaun. 
 
 
Table 17. Estimation of the immunostaining intensity of Nε-(carboxymethyl)lysine in 
the layers of the aortic wall. 
 
Group     Intima     Media  Adventitia 
Control 1.40 ± 0.41 0.79 ± 0.37 1.96 ± 0.39 
Diabetes 2.79 ± 0.39# 2.07 ± 0.45# 2.86 ± 0.24#
Diabetes + vitamin D 2.79 ± 0.39# 1.30 ± 0.27* 2.50 ± 0.35 
 
The staining intensity was expressed by a scale ranging from 0 to 4 (0 – no staining, 1 – 
weak staining, 2 – moderate staining, 3 – strong staining, 4 – very strong staining). The 
scores were summed and the values are presented as means ± SD. 




5.2. Markers of endothelial dysfunction and  
oxidative stress in diabetes mellitus  
(Paper III) 
Serum levels of ADMA were significantly higher in the untreated diabetic 
group compared to the control group (Table 2). TPX levels in the liver 
homogenates were significantly higher in the untreated diabetic group than in 
the control group (Figure 12). Liver TAC levels were significantly lower and, as 
a result, OSI was significantly higher in the untreated diabetic rats, compared to 
the control rats (Figures 13 and 14). The levels of serum TAC were 





Figure 12. Total peroxide levels in the liver were significantly increased in untreated 




































Figure 13. Untreated diabetes was associated with reduced total antioxidant capacity in 




Figure 14. Oxidative stress index in the liver was significantly increased in untreated 
diabetes. Oxidative stress index is expressed as the per cent ratio of TPX to TAC. Data 















































































Figure 15. Serum total antioxidant capacity was significantly decreased in untreated 
diabetic rats. Data are mean ± SD. TAC, total antioxidant capacity. 
 
 
5.3. Vascular protection  
by vitamin D and telmisartan (Papers I–III) 
5.3.1. Effect of vitamin D on diabetic  
vascular complications (Papers I and III) 
Administration of vitamin D resulted in significantly higher serum 25(OH)D 
levels compared to the control group (Table 2). However, vitamin D supple-
mentation did not prevent the elevation of serum ADMA concentration (Table 
2). Serum calcium levels were similar between all groups (Table 2). 
 The non-linear PWV-MAP curve for the diabetic treated group was similar 
to that of diabetic untreated group, indicating that aortic stiffness was similar at 
every given level of MAP (Figure 5). Although all three groups received similar 
doses of PE, MAP above 170 mmHg was not achieved in vitamin D treated rats. 
The reason for this effect is unknown, but may possibly include a lower 
sensitivity to phenylephrine. 
 Compared to the untreated diabetic group, milder changes within the aortic 
wall, particularly regarding medial elastic fibres with no focal disarrangements, 
were noted in the diabetic treated group (Table 15, Figure 8). Treatment with 
vitamin D also restored the reduced ratio of elastin to collagen seen in the aortic 
wall of the untreated diabetic rats (Table 15). No focal thickenings or other 
significant alterations of the intimal layer were found neither in the untreated 
nor treated diabetic groups. 
 Vitamin D effectively prevented CML accumulation in the aortic tissue 











































diabetic rats (Figure 14). Furthermore, significant improvement of serum TAC 
was observed in the diabetic treated group where TAC was restored to a higher 
level than that in the control group (Figure 15). 
 Strong immunostaining for CML was still seen in the intimal and adventitial 
layers of the aortic wall in the vitamin D-treated diabetic group, but the thickest 
layer, the media, showed moderate staining, resembling the staining pattern in 
the control group (Table 17, Figure 11). 
 
 
5.3.2. Attenuation of diabetes-induced aortic stiffening and 
remodelling by telmisartan (Paper II) 
Resting anaesthetised SBP, DBP, and MAP were significantly lower in the 
telmisartan-treated diabetic group, compared to the other two groups. HR was 
significantly lower than that in the untreated diabetic group. Decreased dP/dt 
associated with untreated DM was partially attenuated by telmisartan. As a 
result of significantly lower resting MAP in the telmisartan group, pressure-
dependent PWV values were also significantly lower in that group. 
 The intercepts and coefficient in = + × + × 2 were 
not significantly different between the treated and control groups (Tables 8, 10, 
and 12). Robust methods ANCOVA revealed that the untreated DM and treated 
diabetic groups differed at all MAP levels other than 60, 110, 120, 130, and  
150 mmHg (Table 18). Controls were not significantly different to treated 
animals at any MAP value (Table 19). 
 
 
Table 18. Robust method analysis of covariance, Diabetes (D) vs Diabetes + 
telmisartan (DT). 
 
MAP n1 n2 DIF TEST SE CI.low CI.hi P value crit.val
60 10 21 0.12 0.98 0.12 –0.38 0.62     0.36 4.12 
70 21 35 0.19 3.95 0.05   0.04 0.34   <0.001 3.10 
80 28 40 0.21 4.51 0.05   0.07 0.36   <0.001 3.07 
90 32 43 0.23 3.98 0.06   0.06 0.41   <0.001 3.01 
100 36 45 0.16 2.08 0.08 –0.07 0.40     0.04 3.01 
110 38 44 0.11 1.07 0.11 –0.20 0.43     0.29 2.99 
120 39 42 0.16 1.43 0.11 –0.17 0.48     0.16 2.99 
130 38 40 0.25 2.01 0.12 –0.12 0.62     0.05 3.00 
140 39 40 0.36 2.13 0.17 –0.15 0.86     0.04 3.00 
150 38 39 0.35 1.70 0.21 –0.27 0.98     0.10 3.02 
160 38 33 0.53 2.37 0.22 –0.15 1.21     0.02 3.03 
170 35 21 0.88 3.80 0.23   0.17 1.58   <0.001 3.06 
 
MAP, mean arterial pressure; SE, standard error; CI, confidence interval. 
 
Treatment with telmisartan significantly inhibited the diabetes-induced reduction 
of thoracic aorta lumen diameter but did not affect the width of the medial layer 
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(Table 16). The staining intensity of medial elastic fibres was not different from 
the controls. Furthermore, treatment with telmisartan preserved the regularity of 
the arrangement of elastic fibre arrangement (Figure 9). Collagen concentration 
was not statistically different between the untreated and treated diabetic groups 
and the ratio of elastin to collagen tended to increase in the telmisartan group but 
still remained lower than that in the control group (Table 16). 
 
 
Table 19. Robust method analysis of covariance, Diabetes + telmisartan (DT) vs 
Control (C). 
 
MAP n1 n2    DIF TEST SE CI.low CI.hi P value crit.val
60 23 21 –0.01 0.20 0.06 –0.20 0.18 0.85 3.12 
70 42 35  0.01 0.15 0.05 –0.13 0.14 0.88 3.00 
80 45 40  0.05 1.34 0.03 –0.06 0.15 0.19 2.99 
90 46 43  0.08 1.62 0.05 –0.06 0.22 0.11 2.99 
100 45 45  0.05 0.69 0.08 –0.18 0.28 0.49 3.02 
110 45 44 –0.00 0.04 0.09 –0.29 0.28 0.97 3.02 
120 45 42 –0.02 0.21 0.10 –0.32 0.27 0.83 3.00 
130 45 40 –0.01 0.06 0.12 –0.37 0.36 0.95 3.00 
140 45 40  0.01 0.05 0.13 –0.40 0.41 0.96 3.00 
150 45 39 –0.09 0.56 0.15 –0.54 0.37 0.57 2.99 
160 45 33 –0.02 0.11 0.16 –0.49 0.45 0.92 3.00 
170 44 21  0.15 0.90 0.17 –0.37 0.68 0.37 3.06 
 
MAP, mean arterial pressure; SE, standard error; CI, confidence interval. 
 
 
5.4. Association of vitamin D status with  
aortic stiffness in professional soldiers (Paper IV) 
5.4.1. Basic characteristics and laboratory values 
Of the 65 soldiers who completed pre-deployment testing, 10 soldiers did not 
complete post-deployment testing due to injury, incomplete deployment period, 
non-deployment, or no-shows for testing. The baseline characteristics are 
presented in Table 20. 
There were significant changes in various markers of inflammation during 
the mission (Table 21). Plasma 25(OH)D was increased by 2.6 times in com-
parison with baseline values (40 ± 15 vs 104 ± 24 (nmol/L), P <0.001). 
 
 
5.4.2. Haemodynamic parameters 
The post-deployment values for the indices of arterial stiffness (e.g., AIx, PWV) 
did not differ significantly from the baseline values. Brachial and aortic BP, 
MAP, and other haemodynamic parameters remained unchanged when com-
pared with pre-deployment values (Table 22). 
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5.4.3. Association between  
the change of 25(OH)D and the change of aortic PWV 
There was a significant negative correlation between the change of aortic PWV 
and the change 25(OH)D (∆25[OH]D) in soldiers with ∆25(OH)D above 
median (>64 nmol/L, r=–0.44, P=0.02; Figure 16). This correlation was even 
stronger in the 4th quartile of ∆25(OH)D (>82.5 nmol/L, r=–0.6, P=0.02). How-
ever, we did not find similar correlations between 25(OH)D and other para-
meters of arterial stiffness, i.e., AIx and AIx@75. 
 
 
Table 20. Baseline characteristics of the study group before the mission. 
 
Variable       Value 
Age (years)      26 ± 4 
Weight (kg)      79 ± 10.6 
Height (cm)    182 ± 7 
Body mass index (kg/m2)   23.8 ± 2.7 
Smoking (%)          60     
VO2max/kg (mL/kg/min)   53.8 ± 6.1 
Glucose (mmol/L)     4.6 ± 0.6 
Total cholesterol (mmol/L)     4.1 ± 0.8 
HDL (mmol/L)     1.3 ± 0.3 
LDL (mmol/L)     2.4 ± 0.8 
Triglycerides (mmol/L)     1.1 ± 0.6 
Peripheral SBP (mmHg) 124.2 ± 9 
Peripheral DBP (mmHg)   65.6 ± 7.6 
Peripheral PP (mmHg)   56.7 ± 11.1 
MAP (mmHg)   82.3 ± 8.5 
Central SBP (mmHg) 102.9 ± 9   
Central DBP (mmHg)   67.1 ± 8.4 
Central PP (mmHg)   35.8 ± 6.4 
Heart rate (beats/min)   60.8 ± 10.7 
AIx (%)   –3.6 ± 9.6 
AIx@75 (%) –10.8 ± 9.7 
aPWV (m/s)     6.4 ± 1.2 
 
VO2max/kg, maximal oxygen consumption per kg body weight; HDL, high-density 
lipoprotein; LDL, low-density lipoprotein; SBP, systolic blood pressure; DBP, diastolic 
blood pressure; PP, pulse pressure; MAP, mean arterial pressure; AIx, augmentation 
index; AIx@75, augmentation index corrected for a heart rate of 75 beats per minute; 











































   
   





   
   

































   
   









   
   


































   









   































   
   







   
   
























   







   








































































































































































































































































































































































































Table 22. Haemodynamic variables before and after the mission. 
 
Variable         Before          After P value 
Peripheral SBP (mmHg)     124.2 ± 9.0    123.1 ± 9 0.3 
Peripheral DBP (mmHg)       65.6 ± 7.6      66.0 ± 61 0.8 
Peripheral PP (mmHg)       56.7 ± 11.1      57.1 ± 6.6 0.2 
MAP (mmHg)       82.3 ± 8.5      84.1 ± 7.5 0.1 
Central SBP (mmHg)     102.9 ± 9.0    104.0 ± 7.5 0.5 
Central DBP (mmHg)       67.1 ± 8.4      68.3 ± 7.2 0.3 
Central PP (mmHg)      35.8 ± 6.4      35.7 ± 7.8 0.7 
Heart rate (beats/min)      60.8 ± 10.7      62.3 ± 8.5 0.3 
AIx (%)      –3.6  ± 9.6      –3.8 ± 9.1 0.8 
AIx@75 (%)    –10.8 ± 9.7      –9.9 ± 8.3 0.6 
aPWV (m/s)        6.4  ± 1.2        6.3 ± 0.8 0.2 
 
SBP, systolic blood pressure; DBP, diastolic blood pressure; PP, pulse pressure; MAP, 
mean arterial pressure; AIx, augmentation index; AIx@75, augmentation index 






Figure 16. Correlation between the change of aortic PWV and the change of 25(OH)D 
in soldiers with the change of 25(OH)D above median (>64 nmol/L, n=27).  
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6. DISCUSSION 
6.1. Characterisation of pressure-dependent aortic 
stiffness in experimental diabetes mellitus 
Diabetes mellitus is associated with complex metabolic abnormalities in carbo-
hydrate and lipid homeostasis that, among others, lead to major debilitating CV 
complications which are inadequately explained by classic risk factors (Lehto et 
al. 1999). Microvascular changes are a well-known complication of DM 
(Parving et al. 1983) but pathological changes in the large vessels are also an 
important feature of DM. These include stiffening of the aortic wall which is a 
significant contributing factor to the target organ damage leading to impaired 
coronary perfusion and left ventricular dysfunction (Weber et al. 2004; 
O'Rourke and Hashimoto 2007). Pulse wave velocity is a well-established 
measure of aortic stiffness and large-scale clinical studies have demonstrated its 
utility in predicting the CV risk in patients with DM (Cruickshank et al. 2002; 
Blacher et al. 2012). Current ESC/ESH guidelines for the management of 
arterial hypertension regard aortic PWV greater than 10 m/s as a marker of 
asymptomatic target organ damage (Mancia et al. 2013). 
Major determinants of the development of diabetic macrovascular compli-
cations are the severity and duration of DM. Several authors have investigated 
the elastic properties of large arteries in patients with DM and, in general, 
stiffness of the aorta was found to be increased (Pillsbury et al. 1974; 
Thordarson et al. 1986; Oxlund et al. 1989). However, the study populations are 
often indistinctly defined, including both T1DM and T2DM patients, with a 
large age distribution, with or without complications, and with different 
durations of disease, making these data difficult to interpret and compare across 
different studies. Therefore, it is not well established how early appearance of 
hyperglycaemia is translated into deterioration of large artery function since 
most studies investigating diabetic vascular complications have focused on 
T2DM where it is difficult to separate the impact of hyperglycaemia from that 
of age and confounding factors (e.g., obesity and dyslipidaemia) (Salomaa et al. 
1995). Studies in T1DM patients have demonstrated that increased arterial 
stiffness is an early phenomenon that occurs before the onset of overt 
macrovascular disease (Romney and Lewanczuk 2001; Sommerfield et al. 
2007) whereas others have shown no difference (Kool et al. 1995; Yu et al. 
2012) or even lower arterial stiffness, compared with healthy subjects 
(Lehmann et al. 1992). These discrepancies may relate to methodologies used 
and lack of adjustment for confounding factors. 
In the present study (Papers I and II), aortic stiffness was studied in a rat 
model of experimental T1DM by measuring aortic PWV under BP-independent 
conditions. Streptozotocin-induced DM is a well-established standard experi-
mental model for studying the pathophysiology of uncontrolled T1DM and its 
complications (Junod et al. 1969). Experimental studies on the effects of 
duration of STZ-diabetes have shown that increased aortic wall stiffness may be 
63 
established as early as 8 weeks after induction of DM (Zhao et al. 2000; Chang 
et al. 2003; Chang et al. 2006). Impaired aortic elastic properties have also been 
demonstrated in rats following 9 weeks of STZ-induced DM (Wolffenbuttel et 
al. 1998). In accordance with previous studies we demonstrate increased aortic 
stiffness in STZ-diabetic rats compared to nondiabetic rats following 10 weeks 
of uncontrolled hyperglycaemia. 
It is important to note that as PWV is strongly dependent on BP (Asmar et 
al. 1995), measurements of PWV can be accurately and independently com-
pared only if obtained over a range of BP that is often not feasible to induce in 
patients. Our study is the first to characterise the aortic stiffness profile mea-
sured as PWV across a wide range of blood pressures (MAP 50 to 200 mmHg) 
in STZ-diabetic rats. The method used for assessment of aortic stiffness in this 
study enables to compare PWV between the experimental groups independently 
of blood pressure. Furthermore, characterisation of the curvilinear relationship 
between PWV and BP may provide additional means for studying structural 
changes implicated in the pathogenesis of DM-induced aortic stiffness. 
We assessed PWV over a wide range of MAP using a vasoconstrictor PE 
and a vasodilator NTG to raise and lower MAP, respectively. Earlier experi-
ments have shown that changes in PWV following intravenous administration 
of vasoactive agents (PE and SNP) result in similar changes in PWV following 
venous occlusion (Butlin 2007). This indicates that PE and NTG used in our 
experiment affect aortic stiffness via regulation of peripheral resistance and do 
not act on the aortic segment being studied. Therefore, the aortic stiffness 
assessed by PWV is only dependent on the effects of DM and not influenced by 
the active effects of infused vasoactive agents. 
In our experiments, differences in isobaric PWV only became evident at the 
high MAP range which demonstrates that intrinsic aortic stiffness was unaltered 
in diabetic animals across the blood pressure range assessed under resting 
anaesthetised conditions. By dissociating PWV and BP, our results indicate that 
during the course of DM, early changes in the arterial integrity are reflected in 
the increased aortic stiffness that can remain undetected since BP may not be 
elevated in that stage as was the case in our experiment. Our findings of similar 
resting BP between the control and diabetic animals are supported by 
experimental studies showing that STZ-diabetic rats may be normotensive at the 
early stage of the disease (Kusaka et al. 1987; Hicks et al. 1998; Chang et al. 
2003). Furthermore, clinical studies have demonstrated that while the early 
course of DM may not be associated with elevated BP (Tarn and Drury 1986; 
Sommerfield et al. 2007), changes in the arterial integrity can already be 
observed as increased large artery stiffness (Giannattasio et al. 2001; Manolis et 
al. 2005; Sommerfield et al. 2007). Therefore, in clinical settings, it is possible 
that increased aortic stiffness may be established only when diabetic patients 
develop hypertension, a common complication later in the course of DM. The 
results from our experiments highlight the importance of adequate and early BP 
control for prevention of diabetic macrovascular complications. The 2007 
ESC/ESH guidelines for treating hypertension in patients with DM put an 
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emphasis on aggressive BP lowering (<130/80 mmHg) to prevent or reduce the 
risk of vascular organ damage (e.g., microalbuminuria and retinopathy) (Mancia 
et al. 2007). However, the evidence favouring aggressive intervention is not 
convincing as demonstrated in the Action to Control Cardiovascular Risk in 
Diabetes trial where no significant reduction in CV morbidity in diabetic 
patients whose SBP was reduced to an average of 119 mmHg, compared with 
patients whose average SBP was 133 mmHg (Cushman et al. 2010). As a result, 
the 2013 ESC/ESH guidelines for treating hypertension recommend that all 
patients be treated to <140 mmHg SBP and patients with DM to <85 mmHg 
DBP (Mancia et al. 2013). The findings from our experiments are in agreement 
with this recommendation in that we did not evidence differences in aortic 
stiffness assessed at lower BP, but with increasing pressure, significant differen-
ces in aortic stiffness were observed between groups, indicating asymptomatic 
target organ damage. 
 
 
6.2. Diabetes-induced structural and functional 
abnormalities in the aortic wall 
The pathogenetic determinants of DM-induced vascular complications are in-
completely understood. Macroscopic atherosclerotic lesions are more prevalent 
in coronary arteries and aortas from diabetic subjects than in arteries from non-
diabetic subjects (Robertson and Strong 1968) but large-scale studies have 
shown that classic risk factors for atherosclerosis, including hypertension and 
dyslipidaemia, do not completely explain the incidence of CVD in patients with 
DM (Garcia et al. 1974; Lehto et al. 1999). In another study in T1DM patients, 
isolated aortic rings without visible atherosclerotic lesions were found to be 
significantly stiffer than those obtained from healthy control subjects (Oxlund et 
al. 1989). Therefore, it his highly probable that primary changes in the arterial 
geometry and morphology, rather than secondary changes due to accelerated 
atherosclerosis, are major factors in the pathogenesis of large artery disease 
among T1DM patients. These disturbances are probably related directly or 
indirectly to persistently elevated levels of blood glucose. In the current study 
we have investigated the role of hyperglycaemia in the genesis of structural and 
functional alterations in the aortic wall (Papers I and II). 
Elastic properties of the aortic wall are strongly dependent on the content of 
two dominating extracellular matrix proteins, collagen and elastin, and their 
orderly arrangement. In our study, a decrease in the amount of elastic lamellae 
in the aortic media was noted in the untreated diabetic group. Furthermore, the 
appearance of elastic lamellae was fragmented and disorderly, compared to 
normal intact wave-like organisation of the elastic lamellae in the control rats. 
Our results are supported by earlier findings of decreased elastin content within 
the aortic wall in rats following 10 days of alloxan-induced T1DM (Kwan et al. 
1988). Importantly, the diabetic rats in their study were normotensive implying 
that modifications of the aortic wall morphology were solely due to the diabetic 
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state, as was also the case in our study. Similar results were produced in another 
study showing a time-dependent loss of elastin within the aortic medial layer in 
normotensive STZ-diabetic rats over a course of 150 days (Searls et al. 2012). 
Our findings are also consistent with observations of deformed structure of 
elastic fibres and a relative increase in collagen content within the aortic wall, 
coupled with reduced aortic distensibility in STZ-diabetes (Sun et al. 2009). 
Differential impairment of the load-bearing elements, elastin and collagen, 
within the aortic wall is concordant with the aortic stiffness profile in the 
untreated diabetic group. With increasing pressure, decreased amount of elastin 
and a relative increase in collagen content cause premature recruitment of stiffer 
collagen fibres, as demonstrated by increased aortic stiffness at the high BP 
range. This hypothesis is supported by in vitro studies on the biomechanical 
properties of elastin and collagen showing that in elastase-digested arteries, with 
increasing stretching, the engagement of collagen fibres occurs more rapidly, in 
contrast to gradual and smooth recruitment in the normal arteries (Fonck et al. 
2007; Kochova et al. 2012). The findings from these studies imply that efficient 
transition from low to high pressure region is dependent on the interaction of 
both collagen and elastin fibres, and loss of elastin may also be responsible for 
abnormal function of collagen fibres. 
There is no consensus in the literature as to whether the concentration of 
collagen is increased, decreased, or unchanged within the diabetic aortic wall. 
Indeed, there are conflicting reports of increased collagen (Reddy 2004), 
decreased collagen and elastin contents (Andreassen and Oxlund 1987), and no 
changes in collagen levels within the aortic wall of diabetic rats (Andreassen et 
al. 1981). These discrepancies are possibly related to methodological diffe-
rences in the collagen quantification and the duration of STZ-diabetes. Further-
more, several authors have implied that alterations in the collagen network 
rather than total collagen content, contribute significantly to the biomechanical 
integrity of the vessel wall (Brüel and Oxlund 1996; Wolffenbuttel et al. 1998). 
Diabetes-induced arterial wall remodelling is a well-established compli-
cation and characterised by thickening of intimal and medial layers. Increased 
carotid artery intima-media thickness has frequently been reported in patients 
with T1DM (Frost and Beischer 1998; Yamasaki et al. 1994) and is considered 
an independent CV risk factor (Mancia et al. 2007). In this regard, our findings 
of reduced width of aortic media in the untreated diabetic group are at variance 
with observations from human studies. However, experimental studies with 
different durations of STZ-diabetes have shown that the width of the aortic 
medial layer may be decreased at an early stage (Searls et al. 2012; Akgün-Dar 
et al. 2007) and gradually increase with the ongoing disease due to vascular 
smooth muscle cell proliferation (Fukuda et al. 2005). The structural alterations 
occurring during the course of DM may involve differential transcriptional 
regulation of matrix metalloproteinases (Song and Ergul 2006) and trans-
forming growth factor-beta (Rumble et al. 1997; Kanzaki et al. 1997). 
We studied the possible causes for changes in the functional and structural 
properties of the aortic wall in STZ-diabetes by examining the modification of 
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extracellular matrix through non-enzymatic glycation and oxidation (Paper III). 
Glycoxidation of proteins within the vascular wall has been proposed as an 
important factor influencing arterial compliance in DM. The proteins 
undergoing glycoxidation are preferably long-lived, and collagen and elastin are 
the main targets within the aortic tissue (Meng et al. 1996; Winlove et al. 1996).  
Advanced glycation end-products represent a heterogeneous family of 
protein adducts with different properties. For example, pentosidine, the first 
AGE characterised, is known to form fluorescent cross-links in collagen and 
other proteins within the vascular wall (Winlove et al. 1996). While normal 
cross-linking is necessary to provide distensibility and mechanical strength to 
the tissue, excessive cross-links may lead to increased stiffness and functional 
disturbances of the vessel wall. Nε-(carboxymethyl)lysine is a compound which 
does not have fluorescence and neither forms cross-links in protein. However, 
increased tissue levels of CML have been found in subjects with DM, as CML 
is known to accumulate in collagen and elastin and irreversibly affect their 
properties (Dyer et al. 1993; Mizutari et al. 1997). Moreover, immunochemical 
methods have identified CML as a dominant AGE antigen (Reddy et al. 1995) 
in various tissues, including the arterial wall. Nε-(carboxymethyl)lysine has also 
been found to be a major AGE recognised by RAGE or scavenger receptors 
involved in the binding of AGEs and eliciting intracellular damage due to their 
co-localisation in various tissues, including vascular endothelium and VSM 
cells (Kislinger et al. 1999; Soulis et al. 1997). In the current study, we have 
used CML as a global marker of AGE formation. Our findings of increased 
deposition of CML within the aortic wall in untreated STZ-diabetes are 
consistent with earlier reports from animal (Meng et al. 1996; Soulis et al. 
1997) and human studies (Nakamura et al. 1993) describing increased 
deposition of AGEs in the arterial wall in the settings of DM. We confirmed our 
findings with an immunohistochemical method using monoclonal anti-CML 
antibody which localised CML in the intima, media, and adventitia, with 
prominent stainings in the intimal and adventitial layers. 
Endothelial dysfunction is regarded as an important early pathophysiological 
event contributing to the development of diabetic vascular damage. Moreover, 
endothelium-derived NO regulates arterial stiffness (Wilkinson et al. 2002). 
Increased deposition of AGEs in the aortic wall may disturb endothelial 
function by inhibiting NO production (Xu et al. 2003) or acting directly to 
chemically inactivate NO and inhibit NO-mediated vasodilation (Bucala et al. 
1991). Another important regulator of NO bioavailability is endogenously pro-
duced ADMA. In our study, the serum levels of ADMA, a marker of endo-
thelial dysfunction, were significantly elevated in untreated STZ-diabetic rats. 
These findings are accordance with studies showing that endothelial dys-
function occurs early in the course of DM, as evidenced by functional 
assessment of the endothelium (Serizawa et al. 2011) and concurrently elevated 
levels of circulating ADMA (Xiong et al. 2005; Altinova et al. 2007). 
The cause for the increase of serum ADMA levels in diabetic rats is not 
clear. First, the renal function should be considered because ADMA is excreted 
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via the kidneys and has been shown to accumulate in patients with chronic renal 
failure (Vallance et al. 1992). Although we did not assess renal function in this 
study, it is well-established that diabetic individuals are susceptible to renal 
damage (Warram et al. 1996) and it is possible that renal ADMA clearance was 
decreased in STZ-diabetic rats in our study. In contrast, there have also been 
reports on similar serum ADMA levels in renal disease patients with normal 
renal function, moderate renal failure, and advanced renal failure (Kielstein et 
al. 2002). This raises a possibility that an increase in serum ADMA may be due 
to stimulated production or impaired degradation rather than reduced excretion. 
Indeed, the expression and activity of dimethylarginine dimethylamino-
hydrolase, an enzyme responsible for ADMA degradation, has been found to be 
decreased in the aortas of STZ-diabetic rats (Lin et al. 2002; Lu et al. 2010). 
Importantly, it has been suggested that serum ADMA levels may be 
dependent on the severity of DM rather than the duration of the disease (Xiong 
et al. 2005). This view is supported by an earlier study showing higher risk of 
developing CV complications in diabetic patients with poor glycaemic control, 
compared to patients with good glycaemic control (Andersson and Svardsudd 
1995). Furthermore, ADMA levels and endothelial dysfunction can be reversed 
after chronic insulin treatment in STZ-diabetes (Xiong et al. 2003). Collec-
tively, these results support the use of ADMA as an early marker of endothelial 
dysfunction in the development of diabetic vascular complications. 
 
 
6.3. Significance of oxidative stress and  
antioxidant status in experimental diabetes mellitus 
The role of antioxidant defence/protection and OxS in DM has been studied 
extensively and mounting evidence supports the concept that impaired 
antioxidant defence in concert with increased OxS has a strong impact on the 
pathogenesis of diabetic vascular disease. Sustained hyperglycaemia promotes a 
pro-oxidant environment that is exacerbated by concurrent generation of AGEs. 
Indeed, all AGEs accumulated in the tissue proteins require pro-oxidative 
environment for their formation (Baynes 1991). This implies that the levels of 
AGEs in the target organ may not only reflect long-term cumulative metabolic 
stress (i.e., hyperglycaemia) but also serves as a combined measure of both OxS 
and carbonyl stress. 
 Under normal and pathological conditions, mitochondria are considered to 
be the major source of endogenously produced ROS (Nohl 1994). The liver is 
heavily dependent on mitochondrial oxidative metabolism for its ATP require-
ments, and elevated levels of ROS cause mitochondrial damage that can gene-
rate further elevated OxS in the cells. Furthermore, the liver is a central organ in 
glucose homeostasis, and many important metabolic pathways involved in the 
pathogenesis of metabolic disorders in DM are localised in the liver. We 
assessed the level of OxS and total antioxidant status in the untreated STZ-
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diabetic rats by measuring the concentrations of TPX and TAC in the liver and 
TAC in the serum samples (Paper III). 
The assay for measuring TPX in the target tissue provides information about 
the levels of all derivatives of peroxides produced in the organism and can be 
regarded as reliable index of OxS status because it is indicative of oxidative 
products of lipids, peptides, and amino acids. The capacity of plasma and 
tissues to counteract the effects of OxS may be assessed by measuring the 
activities of individual antioxidants, whereas quantifying the combined capacity 
of all antioxidants provides additional information about the synergistic effects 
of different antioxidants to neutralise reactive species. The total antioxidant 
capacity assay is used widely to assess the contribution of different antioxidants 
to neutralise reactive species (Re et al. 1999; Erel 2004). 
In agreement with previous studies (Kakkar et al. 1998; Feillet-Coudray et 
al. 1999; Sun et al. 1999), we show that the susceptibility to oxidation is 
significantly increased in the liver of untreated STZ-diabetic rats, as evidenced 
by increased levels of TPX. However, we found that TAC in the liver was 
unchanged which is probably the result of markedly improved self-protection 
against OxS, possibly by increased levels of bilirubin (Sudnikovich et al. 2007), 
vitamin E and coenzyme Q (Santos et al. 2001; Feillet-Coudray et al. 1999), 
and GSH (Raza et al. 2004). To gain more information regarding the redox 
balance between oxidation and antioxidation we also calculated OSI, which is 
the ratio of TPX to TAC. As expected, OSI was significantly higher in the 
untreated diabetic rats, compared to healthy rats. Thus, increased production of 
peroxides in the diabetic liver indicates increased susceptibility to oxidation in 
spite of activated antioxidant system. These findings are at variance with those 
reported in an earlier study, demonstrating decreased lipid peroxidation in 
diabetic rats paralleled by increased levels of vitamin E and coenzyme Q in the 
liver (Santos et al. 2001). However, the rats used in that study were a model of 
T2DM with considerably lower blood glucose levels, compared to untreated 
STZ-diabetic rats in our study (11 mmol/L vs 28 mmol/L, respectively), and 
were studied at a very early stage of DM reportedly not associated by 
complications. 
Significantly lower levels of serum TAC observed in the untreated diabetic 
rats reflect a severely compromised systemic antioxidant response to the 
elevated OxS. Our results are in accordance with those reported by other 
investigators demonstrating decreased plasma radical-trapping potential in 
experimental (Feillet-Coudray et al. 1999) and clinical DM (Tsai et al. 1994; 
Santini et al. 1997). Major contributors to serum TAC are albumin, uric acid, 
and ascorbate, largely due to their relatively high concentrations compared to 
other antioxidants in the blood such as bilirubin, α-tocopherol, and β-carotene 
(Miller et al. 1993; Erel 2004). Lower serum TAC may be linked to hypo-
albuminaemia as observed previously (Asayama et al. 1994; Feillet-Coudray et 
al. 1999); this is also consistent with the reported contribution of albumin to 
TAC (Cao and Prior 1998). Uric acid constitutes about 33% of the mea- 
sured serum TAC in healthy subjects (Erel 2004). In patients with DM, 
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hypouricaemia may contribute to decreased serum TAC (Marra et al. 2002). 
Reduced serum uric acid levels are probably related to increased fractional 
excretion of urate as a result of osmotic diuresis caused by hyperglycaemia. 
Decreased plasma ascorbate concentrations have been reported in clinical 
(Jennings et al. 1987) and experimental DM (Young et al. 1995) which may 
result from increased consumption by increased OxS or failed regeneration of 
oxidised dehydroascorbic acid (DHA) to ascorbate. Excessive consumption of 
reduced nicotinamide adenine dinucleotide phosphate (NADPH) in the 




6.4. Vitamin D improves aortic remodelling and  
oxidative stress in streptozotocin-induced diabetes 
A limited number of interventional studies have investigated the role of vitamin 
D in T1DM. Most data regarding the association between vitamin D intake and 
the risk of developing T1DM has been obtained from cross-sectional studies. 
Randomised controlled trials have been scarce and have yielded inconsistent 
results. Vitamin D supplementation is often recommended in pregnant women 
and children for prevention of vitamin D deficiency. Data from case-control 
studies have shown decreased risk of childhood-onset T1DM after vitamin D 
supplementation during the first year of life or during pregnancy (Hyppönen et 
al. 2001; Fronczak et al. 2003). However, it remains unclear whether these 
observations were due to increasing vitamin D to supraphysiological levels or 
were simply the result of preventing vitamin D deficiency. Recent studies 
examining the association between maternal intake of vitamin D and the 
development of T1DM in their children have failed to demonstrate a decreased 
risk of the disease as a result of vitamin D supplementation (Marjamäki et al. 
2010; Simpson et al. 2011). These discrepancies may be due to various vitamin 
D doses, baseline 25(OH)D levels, achieved 25(OH)D levels, and various study 
designs. More information is required from prospective studies determining 
both the intake of vitamin D and vitamin D status in the organism to test the 
hypothesis whether only high levels of circulating vitamin D are protective or, 
conversely, only low levels are an increased risk for the disease. Observations 
from animal models of T1DM have shown that vitamin D supplementation in 
neonatal and early period of life do not protect against T1DM in nonobese 
diabetic (NOD) mice or in BioBreeding rats (Mathieu et al. 2004), whereas 
hypovitaminosis D in the early life doubles the occurrence of DM in NOD mice 
(Giulietti et al. 2004). The aetiology of STZ-induced DM is different from the 
phenotype of NOD mice in that STZ administration results in dose-dependent 
toxic β-cell necrosis, whereas in NOD mice, DM develops as autoimmune 
insulitis. Although some studies have reported improvement of glucose 
homeostasis in STZ-diabetic rats receiving vitamin D (Del Pino-Montes et al. 
2004; de Souza Santos and Vianna 2005), there are also studies that show no 
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improvement of metabolic control with vitamin D supplementation (Noyan et 
al. 2005; Calle et al. 2008). Differences in the doses and forms of vitamin D 
(cholecalciferol or calcitriol), and severity and duration of DM may explain 
these discrepancies. In our study, very high levels of blood glucose and HbA1c 
in both treated and untreated STZ-diabetic rats indicated severely compromised 
glucose homeostasis, and the lack of protective effect of vitamin D supple-
mentation may be attributed to a limited number of surviving insulin-producing 
β-cells incapable of correcting this profound metabolic derangement. 
Suboptimal vitamin D status in patients with DM has been associated with 
increased arterial stiffness (Lee et al. 2012) and endothelial dysfunction (Yiu et 
al. 2011) independent on other CV risk factors. However, data on the impact of 
vitamin D supplementation on the vascular complications of DM are conflicting 
due to a small number of randomised controlled trials and heterogeneity 
between studies. A single dose of 100,000 IU vitamin D has been shown to 
improve BP and endothelial function in vitamin D-deficient (25[OH]D <50 
nmol/L) T2DM patients after 8 weeks (Sugden et al. 2008). However, a follow-
up study in T2DM patients with higher 25(OH)D levels (<100 nmol/L) did not 
show any improvement of endothelial function 16 weeks following a single 
dose of 100,000 or 200,000 IU of vitamin D (Witham et al. 2010). Similarly, 
daily supplementation of vitamin D 5000 IU for 12 weeks did not have any 
significant effect on endothelial function and arterial stiffness in T2DM patients 
with circulating 25(OH)D levels of <30 nmol/L (Yiu et al. 2013). In our study, 
pressure-independent aortic stiffness in diabetic animals receiving vitamin D 
was similar to that of diabetic untreated animals. Furthermore, there were no 
differences in serum levels of ADMA between the two diabetic groups. These 
findings may be attributed to the fact that the levels of blood glucose and HbA1c 
were unaffected by significantly improved vitamin D status, suggesting that the 
possible favourable effects of vitamin D against DM-induced increase in aortic 
stiffness and endothelial dysfunction may have been offset by the sustained 
high-grade hyperglycaemia. 
Although vitamin D supplementation could not protect from the early 
impairment of large artery function it still had a positive effect on the relative 
preservation of elastic fibre organisation in the medial layer of the aortic wall. 
The mechanisms involved in this process remain unclear, but may include the 
down-regulation of the RAS (Li et al. 2002; Dong et al. 2012) since Ang II is 
known to stimulate tissue remodelling in the arteries (Levy et al. 1996) and 
agents that inhibit this system have been shown to have beneficial effects on the 
structural properties of the arterial wall (Albaladejo et al. 1994; Levy et al. 
1996). While there are reports of adverse effects of vitamin D on the elastic 
lamellae within the aortic wall (Niederhoffer et al. 1997; Norman et al. 2002), 
the doses of vitamin D used in those studies were considerably larger and are 
also known to induce calcification and loss of collagen within the arterial wall 
(Niederhoffer et al. 1997). Regarding the risk of inducing hypercalcaemia and 
soft tissue calcification, the dose of cholecalciferol 500 IU/kg used in our study 
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may be considered safe as indicated by similar serum calcium levels in all study 
groups.  
Some AGEs (e.g., pentosidine) are directly derived from the non-enzymatic 
reactions between proteins and carbohydrates, while a combination of glycation 
and oxidation reactions is required for the formation of CML (Fu et al. 1996). 
The relationship between OxS and the formation of AGEs has been established 
by studies showing that the generation of AGEs and protein cross-linking is 
significantly suppressed under antioxidative conditions without an effect on 
overall glycation of proteins (Chace et al. 1991; Fu et al. 1992; Fu et al. 1994; 
Baynes 1991). These results suggest that inhibition of autoxidative glycation 
and glycoxidation, rather than glycation, may be the relevant pathogenetic 
mechanisms in DM. In our study, vitamin D supplementation inhibited CML 
deposition in the medial layer of the aortic wall in the presence of ongoing 
hyperglycaemia. This implies that vitamin D is involved in other important 
mechanisms of CML formation. To our best of knowledge, this is the first study 
demonstrating such an inhibitory effect of vitamin D on CML accumulation. 
The mechanism underlying this finding remains to be established, but it is 
plausible that vitamin D interferes with the formation of ROS by upregulation 
of antioxidant enzymes through VDR signalling (Hamden et al. 2009; Dong et 
al. 2012). Furthermore, in vitro studies have shown that vitamin D reduces 
endoplasmic reticulum stress (Riek et al. 2012) and downregulates the expres-
sion of RAGE (Talmor et al. 2008). Our findings underscore the importance of 
OxS and antioxidant status in the development of diabetic vascular damage. 
Indeed, among diabetic populations, a considerable variance in the rates of AGE 
accumulation, despite similar blood glucose and HbA1c levels, has been 
demonstrated which may be attributed to individual variations in OxS status 
(McCance et al. 1993). 
The liver is central to the vitamin D metabolism and circulation in that liver 
converts absorbed vitamin D into 25(OH)D, the circulating form vitamin D, 
which is the best indicator of vitamin D status in the organism (Zittermann 
2006). Thus, we aimed to assess the impact of vitamin D pooled in the liver on 
the increased OxS, as seen in the untreated diabetic rats. We found that 
supplementation of vitamin D was able to reduce the levels of TPX and OSI to 
those observed in normal rats, clearly demonstrating the antioxidative potential 
of vitamin D. These results are in line with those by Hamden et al. who showed 
that OxS in the diabetic liver may be improved by calcitriol (Hamden et al. 
2009). Moreover, we found that treatment of diabetic rats with vitamin D 
restored the serum TAC to a level that was significantly higher than that found 
in control rats. Detailed explanation to the antioxidative effects of vitamin D 
cannot be provided, but these may include stabilisation of the plasma membrane 
against lipid peroxidation (Wiseman 1993) or upregulation of antioxidant 
systems, including GSH, GSH peroxidase, and superoxide dismutase, via its 
nuclear receptors (George et al. 2012; Sezgin et al. 2013). Treatment with non-
calcaemic vitamin D analogues has been a focus of recent research. In a rat 
T2DM model, it was shown that treatment with 22-oxacalcitriol, a VDR 
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agonist, reduced both systemic and local OxS in the aortic wall through the 
suppressed gene expression of NADPH oxidase to the same degree as insulin 
despite unaffected high blood glucose levels (Kono et al. 2013). The importance 
of VDR in regulating OxS has been demonstrated in several studies reporting 
significant relationship between OxS and VDR loss in VDR knockout mice 
(Kallay et al. 2001; Kallay et al. 2002). These observations suggest that VDR 
agonists, including calcitriol, may have antioxidative effects not by reducing 
hyperglycaemia, but through VDR signalling. 
 
 
6.5. Angiotensin II type 1 receptor blocker telmisartan 
attenuates diabetes-induced aortic stiffening and 
remodelling 
In patients with DM, the prevalence of hypertension is twice as high as in non-
diabetic individuals (Klein et al. 1996). Furthermore, even in individuals with 
normal BP the diagnosis of DM is associated with a moderate to high added risk 
of a 10 year fatal or non-fatal CV event (Mancia et al. 2007). Among a large 
range of antihypertensive agents with equipotent BP lowering effects there is an 
increasing need for individualisation of treatment based on the underlying 
disease and concomitant abnormalities (Mancia et al. 2009). Moreover, there is 
increasing awareness that several antihypertensive agents may have adverse 
metabolic effects while some agents may be particularly beneficial for patients 
with metabolic syndrome or DM regarding their effects beyond BP reduction 
(Mancia et al. 2006). For these reasons, early identification of those at high risk 
and targeted therapy are essential for treatment and prevention of CV 
complications associated with DM. 
Activation of the RAS is an integral mechanism in the pathogenesis of CVD 
in DM and large trials have demonstrated considerable benefit of the blockade 
of RAS for target organ protection (Ball 2003). Renin-angiotensin system 
inhibitors are also preferable to other antihypertensive agents to be used in the 
management of hypertension in patients with DM (Mancia et al. 2007; Mancia 
et al. 2013). Telmisartan has attracted particular interest as an ARB with 
significant favourable effects against tissue remodelling in addition to 
equipotent BP reducing effects, compared to other RAS inhibitors, captopril or 
losartan (Wagner et al. 1998). Treatment of STZ-diabetic rats with telmisartan 
has been shown to reduce DM-induced increase in left ventricular collagen 
deposition and improve left ventricular contractility (Goyal et al. 2008; Goyal et 
al. 2011). Furthermore, telmisartan may improve endothelial function in 
patients with T1DM (Ceriello et al. 2007) and reduce arterial stiffness in 
patients with T2DM (Asmar et al. 2002). 
In accordance with previous studies we report that treatment of STZ-diabetic 
rats with telmisartan for 10 weeks was able to inhibit the development of DM-
induced aortic stiffening in the context of improved structural properties of the 
aortic wall. Specifically, telmisartan preserved the amount of elastin within the 
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medial layer of the aorta and maintained the normal organisation of elastin 
network. These effects were also associated with a modest, but insignificant, 
increase in the ratio of elastin to collagen. The anti-fibrotic effects of 
telmisartan were evident despite the lack of or minimal effect on glucose control 
or body weight. To our best of knowledge the current study is the first to report 
that the ARB telmisartan modulates DM-induced aortic stiffening and 
remodelling independently on BP reduction. Although we did not specifically 
address the possible reasons for these outcomes, previous studies have 
demonstrated that, in addition to direct inhibition of the pro-fibrotic effects of 
Ang II, treatment with RAS inhibitors may have indirect pressure-independent 
protective effects by interfering with AGE formation via antioxidative 
mechanisms (Miyata et al. 2002). Interestingly, telmisartan has also shown 
inhibitory effects on vascular proliferation in cells lacking Ang II receptors, 
suggesting that other mechanisms may be equally important in the ARB-
mediated vascular protection (Benson et al. 2008). 
In summary, we have shown that the ARB telmisartan prevents aortic 
stiffening associated with untreated STZ-diabetes in parallel with favourable 
effects on the structural properties of the aortic wall such as preservation of the 
concentration and organisation of elastin network. These results provide further 
evidence that inhibition of the RAS has a specific role in the prevention of DM-
induced vascular damage beyond BP lowering effects. 
 
 
6.6. Improvement of vitamin D status is associated with 
decreased aortic stiffness in professional soldiers 
Before deployment to Afghanistan 74% of the soldiers had vitamin D 
insufficiency (serum 25[OH]D <50 nmol/L) according to the current consensus 
(Holick 2007). The pre-deployment measurements in our study were performed 
at the beginning of April when the UVB radiation is still inadequate at northern 
latitudes for endogenous vitamin D synthesis (Barger-Lux and Heaney 2002; 
Robsahm et al. 2004). Our results are in accordance with the findings from an 
epidemiological study by Kull et al. who showed that the prevalence of vitamin 
D insufficiency in Estonia is 73% and 29% in winter and summer, respectively 
(Kull et al. 2009). The mean post-deployment 25(OH)D levels had increased 
2.6 times to a mean value of 104 nmol/L, ranging from 54 nmol/L to 157 
nmol/L. This was an anticipated result regarding that Afghanistan is situated at 
the latitude of 32° N where the synthesis of vitamin D in the skin occurs for 
most of the year owing to high UVB radiation intensity. 
Prolonged strenuous exercise induces a short-term and reversible in-
flammatory response as indicated by increased levels of various cytokines 
(Nieman et al. 2001) and other systemic biomarkers of inflammation, e.g., CRP 
(Andersson et al. 2010). Under chronic conditions low-grade systemic 
inflammation is associated with increased arterial stiffness (Yasmin et al. 2004; 
Kampus et al. 2004). Soldiers are often engaged in prolonged difficult physical 
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activities during military operations. This may result in deleterious implications 
on the immune system (Bernton et al. 1995; Gomez-Merino et al. 2003) and 
induce an acute systemic inflammatory response leading to impaired vascular 
function (Kampus et al. 2008). Consistent with previous studies we observed 
significant changes in the spectrum of pro- and anti-inflammatory biomarkers 
after the mission in the absence of clinically relevant inflammation. These 
results support the hypothesis by Ostrowski et al. that the inflammatory 
response to stress or exercise involves both pro- and anti-inflammatory 
activities (Ostrowski et al. 1999). Furthermore, a low-grade ongoing immune 
activation has also been reported in studies including veterans with Gulf War 
Illness (Skowera et al. 2004; Whistler et al. 2009). However, despite the 
presence of a low-grade inflammatory response after the mission we did not 
evidence any significant differences in the parameters of arterial stiffness. 
Therefore, we hypothesise that the immunoregulatory effects of high levels of 
25(OH)D in all soldiers may have attenuated the possible inflammation-induced 
adverse effects on the vascular function resulting in a neutral net effect on 
arterial stiffness. In regard of possible favourable effects of high levels of 
vitamin D on vascular function we assessed the correlation between the pre- and 
post-deployment levels of aortic PWV and 25(OH)D. We found that increased 
25(OH)D levels were associated with decreased aortic PWV in a subgroup of 
soldiers with the highest increase in 25(OH)D levels. Although biologically 
plausible, the association we observed between the change of aortic PWV and 
the change of 25(OH)D in this subgroup does not necessarily indicate a causal 
link between arterial stiffness and vitamin D status in our study, and larger 




1. Streptozotocin-induced model of type 1 diabetes mellitus (STZ-T1DM) in 
rats was characterised by increased aortic stiffness, whereas blood pressure 
was not elevated after 10 weeks of the disease. By measuring aortic pulse 
wave velocity across a full range of pharmacologically modulated blood 
pressures we found that increased aortic stiffness only became evident at a 
high mean arterial pressure range, while no differences were detected at a 
lower mean arterial pressure range. These results suggest that increased 
isobaric pulse wave velocity as a measure of aortic stiffness is an early 
indicator of diabetes-induced arterial damage. 
2. Experimental T1DM was associated with a decreased number and disturbed 
integrity of elastin fibres in the medial layer of the aortic wall and an 
increase in collagen content. These changes were expressed as a decrease in 
the ratio of elastin to collagen fibres in the aortic media and reduced 
thickness of the media. High levels of Nε-(carboxymethyl)lysine (CML), a 
major product of oxidative modification of glycated proteins, were 
established in the intimal, medial, and adventitial layers of the aortic wall. 
The localisation of CML within the diabetic aortic wall in conjunction with 
impaired structural integrity of the aorta demonstrates the contribution of 
advanced glycation end-products (AGEs) to the vascular wall damage 
occurring in STZ-T1DM. Oxidative stress-related production of CML within 
the aortic wall suggests a role for CML as an integrative biomarker of long-
term oxidative damage to tissue proteins. 
3. Asymmetric dimethylarginine levels in the serum were increased in rats with 
STZ-T1DM, indicating disturbed endothelial function. Oxidative stress 
index (the ratio of total peroxide level to total antioxidant capacity level) was 
elevated in the liver in STZ-T1DM. Diabetes also resulted in decreased 
serum total antioxidant capacity that indicates a substantially compromised 
systemic antioxidant response to the elevated oxidative stress.  
4. Vitamin D supplementation for 10 weeks after the induction of STZ-T1DM 
in rats prevented the quantitative and qualitative changes in the elastin fibres 
in the aortic wall, but no effect was observed on the aortic stiffness in vivo. 
Vitamin D improved serum total antioxidant capacity and decreased 
oxidative stress index in the liver, the key organ in the metabolism and 
circulation of vitamin D. The accumulation of CML in the medial layer of 
the aortic wall was significantly reduced by vitamin D. These findings 
suggest that the vasoprotective effects of vitamin D could be mediated via 
inhibition of the accumulation of AGEs in the aortic wall in the context of 
reduced oxidative stress and improved systemic antioxidant capacity. 
5. Treatment of diabetic rats with an angiotensin II type 1 receptor blocker 
telmisartan for 10 weeks after induction of STZ-diabetes reduced aortic 
stiffness in vivo independently of blood pressure reduction and partially 
preserved the amount and structural integrity of the elastin fibres within the 
aortic wall. The protective effects of telmisartan support the concept that the 
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inhibition of the renin-angiotensin system has a specific role in the improve-
ment of diabetic vascular complications beyond blood pressure reduction. 
6. Long-term exposure to physical and environmental stress during a 6-month 
military mission did not increase aortic stiffness and peripheral or central 
blood pressures in young well-trained professional soldiers. Before the 
deployment, vitamin D insufficiency was prevalent in 74% of the soldiers. 
After the deployment, vitamin D status was normalised in all soldiers. In a 
subgroup of soldiers with the highest increase in vitamin D levels there was 
a significant correlation between the decrease in aortic stiffness and the 
increase in serum vitamin D levels. Significant changes in serum biomarkers 
of inflammation were also established after the mission. In the perspective of 
possible favourable effects of vitamin D on inflammation and vascular 
function we postulate that the overall neutral effect on aortic stiffness may 
have resulted from the interaction between high levels of vitamin D and 
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9. SUMMARY IN ESTONIAN 
Vitamiin D ja angiotensiin II retseptori blokaatori mõju 
arterikahjustustele 
Vitamiin D keskseks biofunktsiooniks on kaltsiumi ja luukoe ainevahetuse 
regulatsioon. Tänapäeval on kindlaks tehtud, et vitamiin D retseptor on ekspres-
seeritud paljudes rakkudes, sealhulgas pankrease β-rakkudes, immuunrakkudes, 
endoteelirakkudes, kardiomüotsüütides ja neuronites. See asjaolu viitab, et 
vitamiin D võib mõjutada kudede ja organite olulisi funktsioone, mis ei ole 
otseselt seotud kaltsiumi ainevahetusega. Kliinilistes uuringutes on leitud, et 
madal vitamiin D tase organismis on seotud kõrgema südame- ja veresoon-
konna (SV) haiguste riskiga, mis väheneb vitamiin D taseme normaliseerudes. 
Vitamiin D normaalse taseme säilitamise tähtsust kinnitavad epidemioloogilised 
uuringud, mis on näidanud, et vitamiin D defitsiit on Põhja-Euroopas levinud 
kliiniline probleem. 
 Arterite seinte jäigenemine on vananemise ja SV haigustega kaasnev prot-
sess, mis on tingitud arterite struktuursete ja funktsionaalsete omaduste muutus-
test. Suurte arterite (sh. aordi) suurenenud jäikus on iseseisev riskitegur SV 
haiguste kujunemisel nii tervetel kui kõrge riskiga inimestel ja spetsiifiline ravi 
sihtmärk. Pulsilaine leviku kiirus aordis on arterite jäikust iseloomustav para-
meeter, mis on ühtemoodi mõõdetav nii inimestel kui katseloomadel. Euroopa 
Hüpertensiooni Ühingu ja Euroopa Kardioloogide Seltsi hüpertensiooni ravi-
juhise järgi on aordi pulsilaine kiirus üle 10 m/s ka asümptomaatilise organ-
kahjustuse marker. 
 Diabeedi korral mitmekordistub SV haiguste risk ja vaskulaarsed tüsistused 
on diabeediga patsientide peamisteks surmapõhjusteks. Seetõttu on väga oluline 
varases staadiumis tuvastada häireid arterite struktuuris ja funktsioonis ning 
määrata ravi. Diabeedi ravi peamiseks eesmärgiks on normaliseerida aine-
vahetuslikud häired, ent tüsistuste leevendamine võib sealjuures jääda puudu-
likuks. Diabeediga kaasnevate arterikahjustuste patogeneesi uurimine katse-
loomadel on väärtuslik võimalus haiguse kulu mõistmiseks ja uute raviees-
märkide leidmiseks. 
 Kestva raske hüperglükeemia tingimustes, mis on dekompenseeritud dia-
beedi peamiseks metaboolseks tunnuseks, toimub intensiivne valkude ja teiste 
biomolekulide mitteensümaatiline glükeerimine, mille tulemusena kuhjuvad 
kudedes, sealhulgas arterite seintes, glükeerimise lõpp-produktid. Rakuvälise 
maatriksi põhivalkude, kollageeni ja elastiini, mitteensümaatiline glükeerimine 
halvendab arteriseina biomehaanilisi omadusi ning vähendab arterite elastsust. 
Glükeerimise lõpp-produktide teket soodustab tugev kestev oksüdatiivne stress, 
mida antioksüdantne kaitsesüsteem ei suuda adekvaatselt vähendada. Glükee-
rimise lõpp-produktid koos tugeva kestva oksüdatiivse stressiga on määrava 
tähtsusega diabeedi vaskulaarsete tüsistuste kujunemisel ning nende taset 
vähendav ravi võib oluliselt parandada diabeediga kaasnevaid arterikahjustusi. 
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 Diabeediga kaasneb reniin-angiotensiin süsteemi liigne aktivatsioon, mis 
tõstab arteriaalset vererõhku ja pikas perspektiivis süvendab arteriseinte re-
modelleerumist ja jäigenemist. Reniin-angiotensiin süsteemi blokaatorid (nt. 
angiotensiini konverteeriva ensüümi inhibiitorid ja angiotensiin II retseptori 
blokaatorid) on laialdaselt kasutusel arteriaalse hüpertensiooni ravis, ent neil on 
ka samavõrd olulisi toimeid, mis ei ole otseselt seotud vererõhu langetamisega. 
Angiotensiin II retseptori blokaatorite rühmast võib telmisartaan olla eelistatud 
ravim diabeediga patsientidele tänu soodsatele metaboolsetele toimetele. See-
pärast võib telmisartaan pakkuda unikaalseid võimalusi diabeedist tingitud 




Peamiseks eesmärgiks oli uurida vitamin D mõju aordiseina struktuursetele, 
funktsionaalsetele ja biokeemilistele näitajatele ning süsteemselt ja sihtorganis 
mõõdetud oksüdatiivse stressi tasemele; samuti uurida angiotensiin II retseptori 
blokaatori telmisartaani mõju arterikahjustuste vähendamisele roti diabeedi-
mudelis. 
 
Uurimuse täpsed eesmärgid olid järgmised: 
1. Hinnata aordi jäikust pulsilaine leviku kiiruse abil streptosototsiin-tekitatud 
(STZ) roti 1. tüüpi diabeedimudelis. 
2. Uurida morfoloogilisi näitajaid aordi histoloogilistel preparaatidel ja glükee-
rimise lõpp-produktide taset aordiseinas roti STZ-diabeedimudelis. 
3. Mõõta asümmeetrilise dimetüülarginiini taset seerumis ning oksüdatiivse 
stressi ja totaalse antioksüdantse vastuse taset seerumis ja maksas roti STZ-
diabeedimudelis. 
4. Hinnata vitamiin D lisamanustamise mõju aordi jäikusele, aordiseina re-
modelleerumisele, oksüdatiivse stressi tasemele ja glükeerimise lõpp-pro-
duktide tasemele roti STZ-diabeedimudelis. 
5. Uurida angiotensiin II retseptori telmisartaani mõju aordi jäikusele ja re-
modelleerumisele roti STZ-diabeedimudelis. 
6. Hinnata seost aordi pulsilaine leviku kiiruse ja vitamiin D taseme vahel ning 
seerumi põletikunäitajate muutuseid noortel treenitud meestel kauakestva 




Wistar liini rottidel tekitati diabeet STZ (65 mg/kg kehakaalu kohta) ühekordse 
süstiga. Ühele katsegrupile manustati 10 nädala jooksul ülepäeviti suukaudselt 
500 IU/kg kehakaalu kohta vitamiin D või iga päev 10 mg/kg kehakaalu kohta 
telmisartaani. 10. nädalal mõõdeti anesteseeritud rottidel invasiivselt pulsilaine 
leviku kiirust aordis. Määrati oksüdatiivse stressi biomarkerite tase ja uuriti 
aordi histoloogilisi preparaate. 
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 Uuringualusteks olid 65 sõdurit, keda uuriti enne ja pärast 6 kuud kestnud 
sõjalist missiooni Afganistanis. Aordi jäikust mõõdeti pulsilaine leviku kiiruse 
abil aordis ja määrati seerumi põletikumarkerite ja vitamiin D tase. 
 
 
Tulemused ja järeldused 
1. Streptosototsiin-indutseeritud diabeediga rottidel suurenes aordi jäikus pärast 
10 nädalat kestnud haigust, kuid arteriaalne vererõhk jäi muutumatuks. 
Mõõtes pulsilaine kiirust aordis farmakoloogiliselt tõstetud ja langetatud 
vererõhkude juures, leidsime, et aordi jäikus on oluliselt suurem kõrge rõhu 
vahemikus, kuid madalate rõhkude juures ei olnud uuringurühmade vahel 
erinevusi. Tulemused viitavad, et vererõhust sõltumatutes tingimustes mõõ-
detud pulsilaine kiirus aordis on diabeediga kaasnevate arterikahjustuste 
varane näitaja. 
2. Eksperimentaalne diabeet vähendas elastsete kiudude hulka ja tõstis kolla-
geenkiudude hulka aordiseina keskkestas, samuti oli häiritud elastsete kiu-
dude struktuurne terviklikkus. Aordiseina kõikidesse kestadesse oli kuhju-
nud Nε-karboksümetüüllüsiin (CML), mis on valkude glükeerimise ja oksü-
datiivse modifitseerimise peamine lõpp-produkt. Nε-karboksümetüüllüsiini 
kuhjumine koos aordiseina struktuursete kahjustustega näitab, et glükee-
rimise lõpp-produktid (AGE-d) mängivad olulist rolli STZ-diabeediga 
kaasnevate vaskulaarkahjustuste kujunemisel. Oksüdatiivse stressiga seotud 
CML teke aordiseinas viitab, et CML võib olla koevalkude pikaajaliste 
oksüdatiivsete kahjustuste integreeritud biomarkeriks. 
3. Streptosototsiin-diabeediga rottidel oli seerumi asümmeetrilise dimetüül-
arginiini tase oluliselt tõusnud, mis viitab endoteeli häiritud funktsioonile. 
Oksüdatiivse stressi indeks (peroksiidide taseme ja antioksüdantse vastuse 
suhe) oli STZ-diabeediga rottide maksas oluliselt tõusnud. Samuti vähenes 
STZ-diabeedi korral seerumi antioksüdantne vastuse tase, mis viitab 
süsteemse antioksüdantse vastuse olulisele dekompensatsioonile. 
4. Vitamiin D manustamine rottidele 10 nädala jooksul pärast STZ-diabeedi 
tekitamist vähendas aordiseina elastsete kiudude kvantitatiivseid ja kvalita-
tiivseid muutuseid, kuid ei avaldanud toimet in vivo mõõdetud aordi jäiku-
sele. Vitamiin D parandas oluliselt seerumi antioksüdantset vastust ning 
vähendas oksüdatiivse stressi indeksit maksas, mis on ühtlasi vitamiin D 
ainevahetuses võtmetähtsusega elund. Aordiseina keskkestas vähenes oluli-
selt vitamiin D toimel CML kuhjumine. Antud tulemused viitavad, et vita-
miin D vasoprotektiivsed toimed võivad olla vahendatud AGE-de kuhjumise 
takistamise kaudu aordiseinas, mille taustal on vähenenud oksüdatiivse 
stressi tase ja paranenud süsteemne antioksüdantne vastus. 
5. Angiotensiin II retseptori blokaatori telmisartaani manustamine 10 nädala 
jooksul pärast STZ-diabeedi tekitamist rottidele vähendas vererõhu langeta-
misest sõltumatult aordi jäikust in vivo ja osaliselt säilitas aordiseina elast-
sete kiudude struktuurse terviklikkuse ja ja hulga. Telmisartaani protektiiv-
sed toimed viitavad, et reniin-angiotensiin süsteemi inhibeerimisel on 
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spetsiifiline roll diabeedi vaskulaarsete tüsistuste parandamisel, mis ei ole 
seotud vererõhu langetamisega. 
6. Pikaajaline füüsiline ja keskkonnast tingitud stress 6 kuud kestva sõjalise 
missiooni ajal ei tõstnud noortel treenitud professionaalsetel sõduritel aordi 
jäikust, perifeerset ega tsentraalset vererõhku. Enne missiooni esines 74%-l 
sõduritest vitamiin D defitsiit ja missioonijärgselt oli kõikidel sõduritel vita-
miin D tase organismis normaliseerunud. Sõdurite alagrupis, kus oli kõige 
suurem vitamiin D taseme tõus, leidsime, et vitamiin D taseme tõus oli 
seotud aordi jäikuse vähenemisega. Missioonijärgselt esines ka olulisi muu-
tusi seerumi põletikunäitajate spektris. Võttes arvesse vitamiin D potent-
siaalseid põletikuvastaseid toimeid, oletame, et oluliselt tõusnud vitamiin D 
tase võis kompenseerida põletikunäitajate muutusi, mistõttu aordi jäikuses 
muutusi ei ilmnenud.  
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